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Lipids are biologically important molecules as they regulate a litany of key cellular 
processes that, when aberrant, result in disease. Since lipids control these regulation 
pathways, it is imperative to understand their properties and exploit them for use in 
advancing therapeutic strategies. The complex environments in which lipids exist have 
historically complicated their understanding, but recent advancements have facilitated 
this effort. In the chapters that follow, we have used synthetic lipid probes to investigate 
the role of signaling lipids as site-specific ligands in the binding of protein effectors and 
developed a high-throughput platform that can be used to rapidly classify protein-
binding partners to phosphoinositide lipids. Using microarray analysis, we have 
achieved high-throughput binding results for the Akt-PH domain to phosphatidylinositol-
(3,4,5)-trisphosphate. In addition, preliminary results from an investigation of how 
multivalency affects profilin binding to phosphatidylinositol-(4,5)-bisphosphate are 
discussed. We have also developed the first known example of liposome modification 
via copper-free click chemistry as an ideal bioorthogonal approach to intact membrane 
derivatization towards targeting applications. Using a microplate surface-based 
immobilization technique, we have reported the derivatization of intact azido-liposomes 
with a biotinylated cyclooctyne by copper-free click chemistry and performed various 
control reactions to ensure labeling is specific and reliable. Additionally, we have 
reported initial findings for the advancement of this liposome immobilization strategy to 
be performed in high-throughput fashion via microarray. In the final chapter, we briefly 
discuss our involvement in a few collaborative efforts including the optimization of a 
 vi 
non-lipid autotaxin inhibitor, synthesis of porphyrin-lipid conjugates for use in 
photocurrent generation systems, and synthesis of several rhodamine dyes for use in 
surface enhanced hyper Raman spectroscopy (SEHRS).  
 
 vii 
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Chapter 1: Introduction 
Lipids are often overlooked biomolecules that were originally thought to simply 
have a structural role in membranes, but they are now known to play critical roles in a 
plethora of physiological events.1-4 Historically, lipid functions have been difficult to 
study because they exist within complex living systems, residing in cellular membranes, 
which complicates matters even further. Lipids have a diverse range of biological 
functions, including recruitment of proteins to membrane surfaces, actions as small-
molecule ligands, and covalent protein modification through lipidation.1,5,6 Lipids are 
also responsible for the transport and localization of many biomolecules through 
membrane budding and fusion.7-9 Defects in these lipid and membrane functions often 
result in disease, and therefore it is imperative to understand and harness the activities 
of lipids. 
Broadly classified, lipids are hydrophobic or amphipathic small molecules. 
According to the LIPID MAPS database, there are eight categories of lipids: fatty acyls, 
glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, 
saccarolipids, and polyketides.10 The research herein focuses on the category of 
glycerophospholipids, or simply phospholipids, as they are the most abundant of the 
lipid species.11,12 A phospholipid is a molecule that consists of a polar region, called a 
headgroup, and a non-polar region, two long chain fatty acid tails. When exposed to 
water, these molecules self-assemble into bilayers, a lipid sheet comprised of two layers 
of interacting lipids. This bilayer is formed because the tails align to maximize their 
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hydrophobic interactions, resulting in the polar headgroups facing outward, toward the 
external aqueous environment.  
1.1 Phospholipids 
Phospholipids can be divided into two main categories, signaling lipids and bulk 
lipids. The bulk lipids include the lipids that primarily play structural role, such as 
phophatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS), 
although these lipids have also been reported to be involved in protein interactions.13-15 
Examples of signaling lipids include diacylglycerol (DAG), phosphatidic acid (PA) and 
the family of seven phosphatidylinositol polyphosphates (PIPns) (Figure 1.1). These 
lipids are found in much lower concentration than the bulk lipids, which further 
complicates their ability to be characterized. For example, a member of the PIPn family 
is found in roughly 0.5-1.0% of the total phospholipid concentration on the inner leaflet 
of the plasma membrane, while PS is present at 25-35%.4 The signaling lipids often act 
as site-specific ligands in interactions that enforce membrane association of proteins 
that play important roles in cell signaling and membrane trafficking.1,4 The subcellular 
localization of these signaling lipids and their binding partners is tightly regulated. 





Figure 1.1. Structures of bulk and signaling lipids where the tail has been represented generically 
since this can consist of different combinations of fatty acids in nature. 
1.2 Signaling Lipids that Bind Proteins 
Protein-lipid binding lies at the heart of many of the most important cellular 
pathways, primarily due to the ability to transmit information from the membrane into 
signaling cascades. Proteins exhibit significant variation in the mode by which they bind 
to lipids present within membranes. Figure 1.2 shows a cartoon depiction of the ways 
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that interact primarily with the headgroups of signaling lipids. H- and I-type are also 
soluble proteins, but their mechanism of protein binding also involves insertion of 
hydrophobic residues into the interfacial region of the membrane. The 
phosphoinositides, mainly the heavily phosphorylated PIP2s and PIP3, bind 
predominantly S-type proteins, but also have interactions with both H- and I-type. Some 
of the specifics of phosphoinositide–protein binding and their pathways associated with 
disease will be further discussed in Chapter 2. A general scheme depicting the way 
these proteins interact with signaling lipids is shown in Figure 1.3, whereby an inactive 
peripheral protein that is located in the cytosol can be recruited to the membrane 
surface by signaling lipids, become activated, and then regulate many downstream 
pathways. 
 
Figure 1.2. Depiction of the binding modes of the three soluble protein types. 
  





















1.3 Assays for Studying Lipid Interactions 
Since the cellular activities of peripheral proteins depend on their membrane 
binding affinities, a sensitive and quantitative assay for membrane affinity is an essential 
tool for understanding the function and regulation of these proteins. Many cellular 
proteins that participate in signaling pathways translocate to cellular membranes in 
response to various stimuli, including lipid second messengers. There are two ways of 
measuring membrane affinity of peripheral proteins: direct assays and separation 
assays. Examples of direct assays include fluorometric, surface plasmon resonance 
(SPR), and calorimetric methods. These assays provide experimental convenience but 
often require protein or lipid modification. Separation assays do not generally require 
modification but require the laborious task of separation.  
1.3.1 Dot-Blot Assays 
One of the most commonly used methods of assessing lipid binding specificity 
uses nitrocellulose membranes that have been spotted with pure lipids and the extent to 
which any protein of interest binds is determined by its interaction with the lipid spots.16-
19 These dot-blot methods are very sensitive, however, they cannot be quantitated 
reliably and a positive result in these assays may only be the result of very low affinity 
binding that has no physiological relevance in the context of a real membrane. 
Therefore, dot-blot assays should only be used as an initial measure to assess binding 





1.3.2 Direct Fluorescence Assays 
Another sensitive and more informative method for detecting membrane–protein 
binding has been fluorescence assays.20 Direct fluorescence assays have been 
performed by using the intrinsic tryptophan fluorescence found on proteins that changes 
due to environmental differences, such as a shorter wavelength, blue shift, and 
fluorescence intensity increase when found in hydrophobic environments as in cell 
membranes. This direct fluorescence method has been used to study the vesicle affinity 
of many proteins including phospholipases, annexin, and synaptotagmin.21-25 Of course, 
these assays require that a tryptophan residue be present in the vicinity of the binding 
domain, which can also be introduced through mutation but may greatly affect the 
protein–binding affinity.  
1.3.3 FRET Assays 
In addition to the direct fluorescence method, there have been Förster resonance 
energy transfer (FRET) based detection methods. FRET is a mechanism for transferring 
the energy from one fluorophore to another based on proximity (10–75 Å, the Förster 
distance). This works by using a FRET-donor and a FRET-acceptor. The donor 
molecule absorbs and transfers energy to the acceptor. If the donor and acceptor are in 
close proximity, FRET is activated, and excitation at the donor wavelength yields a 
fluorescent peak at the acceptor’s emission wavelength. 
FRET assays often use a tryptophan residue as well, but rather than direct 
fluorescence, a fluorescent acceptor lipid is used in tandem. In these assays, the 
protein solution is titrated into a fixed concentration of vesicles or vice versa and the 
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fluorescence changes are monitored. FRET assays have been used to study the 
interactions of proteins such as phospholipases, protein kinases C, and annexins.22,26-34 
These FRET-based assays suffer the same drawback as the direct fluorescence assay 
in that it also requires a tryptophan residue on the protein of interest, but in this case its 
position is not as strictly defined because it does not have to be located in the 
hydrophobic membrane core upon binding, only found within the Förster distance of the 
FRET-partner lipid in the membrane.  
1.3.4 Surface Plasmon Resonance Assays 
In recent years, surface plasmon resonance (SPR) assays have become popular 
for measuring membrane–protein binding interactions. In these assays, lipids are 
immobilized onto the surface of a sensor chip either by attachment of biotinylated 
vesicles via streptavidin interaction or using a sensor chip with hydrophobic anchors in 
which membranes are immobilized directly. A protein solution is then washed over the 
sensor chip and any proteins that bind the lipids remain behind, bound to the lipid. 
These bound proteins are then detected because of the changes in refractive index 
near the surface cause a change in the resonance angle of the incident light. These 
methods are advantageous in that they do not require labeling of the membrane or 
protein and require only a small amount of sample. SPR assays can provide rapid and 
direct determination of dissociation constants, but their determination may not be valid 
when a Langmuir-type binding curve is not valid. Additionally, kinetics of SPR data can 
be quite complex, these experiments require expensive instrumentation, and it is not a 
high-throughput technique. Nevertheless, SPR has been used to determine affinity and 
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specificity of many peripheral proteins including 3-phosphoinositide dependent kinase-1, 
protein kinase C, phospholipase A2, FYVE domain of EEA1, C2 domains of 
synaptotagmin II, mitochondrial creatine kinase, apolipophorin, cytochrome c, recoverin, 
rabbit C-reactive protein, and phosphatidylserine synthase.35-45 
1.3.5 Calorimetry Assays 
Isothermal titration calorimetry (ITC) is another protein–binding assay technique, 
but it has not been used as extensively. In this case, a solution of protein is titrated into 
a cell containing a lipid solution, or vice versa, and the heat released or absorbed is 
measured. This heat exchange is directly proportional to the extent of binding and has 
been used to evaluate binding of several peripheral proteins such as apolipoprotein A-I, 
PDC-109, P-glycoportein and serum albumin.46-49 ITC assays require a relatively large 
amount of sample, which poses a disadvantage for determining high affinity binding, as 
well as requiring expensive instrumentation.  
1.3.6 Lipid Monolayer Penetration Assays 
An assay involving the use of lipid monolayers has also been used to study the 
binding of peripheral proteins to lipids, whereby a monolayer of lipids is formed on the 
aqueous interface in a small trough and the surface pressure is measured. Following 
this, a protein solution is injected into the aqueous layer and the changes in surface 
pressure are measured over time. If a protein binds the lipid and inserts into the 
membrane, the surface pressure is altered and can accurately be measured by this 
technique. This monolayer penetration technique has been used to measure the 
membrane affinity of phospholipases and protein kinases C.50-53 Unfortunately, this 
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assay requires high protein concentrations and cannot be used to determine 
dissociation constants. 
1.3.7 Separation Assays 
In addition to these direct assays, there are other assays involving the separation 
of a protein–lipid complex by centrifugation or chromatography. In the centrifugation 
assays, cell fractionation is performed in which homogenized cell suspensions are 
separated by centrifugation into the supernatant and pellet fractions and the proteins in 
each fraction are quantified. This has been used to study peripheral proteins such as 
protein kinases C, phospholipases, annexins, and synaptotagmins.36,51,54-67 However, 
the long centrifugation in this assay may disturb the delicate equilibriums often seen in 
these protein–lipid complexes, and therefore, determined dissociation constants may 
not represent a true equilibrium constant. Also, based on the lipid composition of the 
vesicles, the pelleting efficiency may vary greatly, as PC vesicles have much lower 
pelleting efficiency than that of anionic vesicles.50 Size-based chromatography assays 
have also been used because they easily separate protein–ligand complexes from large 
vesicles and have been applied to study phospholipases and protein kinase C.23,30,54,68 
This assay is quite easy to perform, but it is not very sensitive. Additionally, it requires 
large protein and lipid samples and an appreciable amount of sample is lost on the 
column in the purification process. Because of these negative aspects of separation 
assays in that they do not always directly represent a protein–ligand equilibrium in true 
cellular context, we have chosen to use a direct assay when investigating our protein–
lipid binding activities. Additionally, prior assays are not high-throughput, which is a 
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driving force for the development of our microarray assay that is further discussed in 
Chapter 2.  
1.4 Membrane Interactions and Fusion 
There are also protein–membrane interactions that regulate other cellular 
pathways and membrane actions such as vesicle budding and fusion.7-9 SNARE 
proteins regulate the fusion of membranes and have been the subject of recent 
research.7,8 The SNARE mechanism works by forming coiled protein strands from 
SNARE proteins embedded within the bilayer of two opposing membranes to bring the 
membranes into proximity and then fuse. Interactions such as this are commonplace in 
nature, but prove to be quite challenging to study in a laboratory setting, as there are 
many complex variables that are difficult to control. For studying these interactions, 
model membrane systems, such as liposomes, micelles, supported lipid monolayers 
(SLMs) and supported lipid bilayers (SLBs), are commonly used to mimic for lipids in 
their native membrane environment and as delivery systems for drugs, genes, and 
imaging agents.16,69-73 There has been a growing interest in understanding and 
harnessing the power of lipid interactions in recent years, but these efforts have met 
significant challenges because of the complex environment in which lipids reside. There 
is, however, a significant need to advance the understanding of lipid function and 






1.5 Bioorthogonal Reactions 
As mentioned, the study of the actions and involvements of lipids in biological 
systems has been hampered by the complex environment in which they exist, but 
advancement in bioorthogonal reactions have greatly impacted the ability to study these 
systems. Bioorthogonal reactions involve two complimentary functional groups that are 
not present in biological systems and do not react with biomolecules, but react well with 
one another. This allows for selective derivatization in complex biological samples. The 
azide group has been the subject for most bioorthogonal reactions because it is a small 
chemical tag that does not cause a large disturbance in the behavior of a molecule, has 
limited inherent reactivity with any existing biological molecule, and has little-to-no 
presence in nature. The three most heavily used bioorthogonal reactions with azides 
have been outlined in Figure 1.4.  
1.5.1 Staudinger Ligation 
The Staudinger ligation came about as the first example of a bioorthogonal 
reaction and has been effective for in vivo labeling.74-78 This reaction uses a phosphine 
reagent to trap the aza-ylide intermediate that is produced through a Staudinger 
reduction reaction. This first example of a bioorthogonal reaction led to many uses, but 
a downfall of this technique is the requisite synthesis of the phosphine reagents, which 
commonly undergoes oxidation.74,79-83  
Glycans are present in massive quantities on cell surfaces, and they play 
important roles in cellular process such as immune responses, inflammation, cancer 
metastasis, and cell-surface recognition, which leads to bacterial and viral cell entry. 
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Thus, their use in bioorthogonal labeling has been investigated and has provided great 
insight into these complex systems.84 A major advancement in the use of bioorthogonal 
chemistry in living systems has been reported by Bertozzi and co-workers whereby 
sugar moieties containing azides can be incorporated into glycoproteins via biosynthetic 
pathways, which her lab then used to perform labeling studies via the Staudinger 
ligation.74,85 These sugars are easily incorporated into the biosynthetic pathways, 
resulting in azido-sialic acid derivatives decorating the surface of cancerous cells, an 
excellent avenue to be exploited for studying and targeting these systems.  
 















Copper Catalyzed Azide-Alkyne Cycloaddition (CuAAC)



























Figure 1.5. Scheme for the incorporation of ManNAc into the biosynthetic pathways and labeling 
via Staudinger ligation.74  
1.5.2 Copper Catalyzed Azide–Alkyne Cycloaddition  
Another bioorthogonal reaction that has been used in recent years is the copper 
catalyzed azide–alkyne cycloaddition (CuAAC). First described by Sharpless, Finn, and 
Kolb, it has now become an invaluable tool for a litany of applications.86-90 This involves 
the use of a cycloaddition first reported by Huisgen involving a terminal alkyne and an 
azide, along with a copper catalyst to join or “click” the two pieces together, yielding a 
triazole in the resulting product. The purpose of click chemistry is to simplify the task of 
synthesizing large molecules and identifying molecules with important biological 
properties. To this end, there have been numerous reports of click chemistry that have 
been used for a wide range of applications.86,87,89,90 A few selected examples of the 








































A report by Tirrell and co-workers showed the incorporation of unnatural amino 
acids bearing azide and alkyne functional groups into proteins.91 This group took 
advantage of lack of differentiation of tRNA synthetases between natural and unnatural 
amino acids, which allowed the incorporation of click-moiety-bearing unnatural amino 
acids into proteins. They have used this methodology to replace methionine with 
homopropargylglycine or azidohomoalanine and phenylalanine with 
azidophenylalanine.92-95 This method can be used to globally replace a natural amino 
acid with its unnatural counterpart, but a more controllable strategy would be the 
incorporation of the azide or alkyne containing unnatural amino acid at a specific 
location, which has been reported by Schultz and co-workers.96-99 They have used this 
methodology to incorporate azide or alkyne labeled unnatural amino acids into 
Escherichia coli, eukaryotic, and mammalian cells.100-102  
Another example of CuAAC is in the report by Wong and co-workers of the 
immobilization of carbohydrates for development of platforms for microarray analysis of 
protein–glycan binding interactions.103-105 This was then used to characterize the 
structural requirements for recognition of the tumor antigen Globo H by antibodies MBr1 
and VK-9, including direct analysis of serum from breast cancer patients.106  
While CuAAC has been used in many applications across a very broad 
spectrum, in vivo applications suffer from toxicity of the requisite copper catalyst. There 
have been efforts in using ligands to first chelate the copper, but even still, cytotoxicity 
exists.107 An additional drawback of CuAAC to in vivo systems is the need to deliver the 
catalyst to the reactive site, adding another layer of complexity. 
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1.5.3 Copper-Free Click Chemistry 
To advance click chemistry for in vivo applications, Bertozzi and co-workers 
developed a strain-promoted azide–alkyne cycloaddition (SPAAC), which involves a 
cyclooctyne moiety and circumvents the need for copper catalyst, and is thus often 
referred to as copper-free click chemistry.108 In this system, the click reaction is 
promoted simply by the strain present in the cyclooctyne ring because it contains an 
alkyne bond, which typically requires a bond angle of 180° but can only achieve a bond 
angle of 163° in the cyclooctyne.109 The initial cyclooctyne 1.1 (Figure 1.6) provided a 
metal-free bioorthogonal substrate that was less prone to oxidation than the Staudinger 
ligation reagents and yielded similar reaction rates.88,108 The recent review by van Delft, 
Rutjes and co-workers outlines the development of various cyclooctyne reagents by 
Bertozzi and co-workers and some of their prominent uses.88 After development of the 
initial cyclooctyne reagents 1.1 and 1.2, it was discovered that these compounds 
decompose even after being stored at -20 °C, so her lab then developed the related 
alkyl-linked cyclooctyne 1.3.108,110,111 This cyclooctyne did not lead to desirable reaction 
rates, and it drove the introduction of fluorines to increase reactivity providing DIFOs 
1.5, 1.6, and 1.7.112,113 Although these second-generation DIFOs have seen many uses, 
Boons and co-workers took a different approach for bioorthogonal labeling using 
cycloooctynes by introducing fused benzenes on either side as in compound 1.8.114 This 
dibenzocyclooctyne (DIBO) was achieved in five synthetic steps and doubled the 
reaction rate of the DIFO compounds.114 While the reaction rates of these cyclooctynes 
are exceptional, all of the previously mentioned cyclooctynes have limited water 
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solubility, a necessary attribute if they are to obtain universal applicability in biological 
systems.88 Bertozzi and van Delft followed similar strategies to increase the water 
solubility of these cyclooctynes by including an amine in the cycloooctyne ring providing 
compounds 1.10 dimethoxyazacyclooctyne (DIMAC) and 1.11 dibenzoazacyclooctyne 
(DIBAC, also called aza-dibenzocyclooctyne (ADIBO)).115,116 On the one hand, in 
DIMAC 1.10, there was a decrease in the reaction rate over the second generation 
DIFO compound 1.7, but when used in Jurkat cells to label metabolically incorporated 
azido-tagged mannose, 1.10 showed significantly less background signal.115 On the 
other hand, in DIBAC (ADIBO) compound 1.11, there was an increase in the reaction 
rate over the parent cyclooctyne, DIBO 1.8, as well as increased water solubility.116 
Continual advancements in the reactivity, stability and synthetic facility of cyclooctyne 
reagents have led to significant improvements in the efficacy and accessibility of this 
chemistry.84,87,114,117-121 The cyclooctynes cited above are meant to provide an overview 
of the development of strain-promoted click-chemistry in recent years, the reports cited 




Figure 1.6. Structures of some of the recently reported cyclooctynes. 
1.5.4 Examples of Bioorthogonal Labeling Using Lipid Probes 
Bioorthogonal chemistry has also found uses in lipid probes. Click chemistry has 
been exploited by Cairo and co-workers in their use of alkyne modified PC and 
sphingomyelin probes seen in Figure 1.7.122 In these probes, one of the methyl groups 
of the choline headgroup has been replaced by an alkyne moiety, and they were then 
labeled by CuAAC using a benzoxadiazole dye resulting in quantitative yields. In this 
study, the sphingomyelin derivatives retained activity in sphingomyelinase assays. 
 
Figure 1.7. Alkyne derivatized sphingomyelin and phosphatidylcholine probes used to label cells 




















1.1 R = p-HO2CC6H4
1.2 R = CO2H
1.3 R = H
1.4 R = F
1.5 DIFO 1.6 R = p-HO2CC6H4
1.7 R = CO2H
1.10 DIMAC1.8 R1, R3 = H, R2 = OH























In a similar strategy involving an alkyne derivatized choline, Salic and co-
workers, instead of synthesizing lipid derivatives, incorporated alkynyl-choline into 
headgroups via biosynthetic pathways and then used them for labeling in live cells by 
CuAAC.123 They successfully hijacked the biosynthetic pathways and incorporated 
these alkynyl-choline moieties into membrane bilayers as evidenced by a copper 
catalyzed click reaction with fluorophores that resulted in a fluorescence signal localized 
and uniformly distributed in the cell membranes. They also investigated the effect of 
alkynyl-choline labeling on cellular lipids and measured its incorporation into cellular 
phospholipids by electrospray ionization-tandem mass spectrometry (ESI-MS/MS) 
analysis of the total lipid suspension. It was discovered that alkynyl-choline does not 
significantly affect the relative abundance of other phospholipids and thus does not alter 
their metabolism.  
Another PC analog has been reported by Smith and co-workers, but in this case, 
the click-reactive moieties are located in the acyl tails instead of the choline 
headgroup.124 In this report, they used a chemo-enzymatic synthetic strategy in that 
they selectively cleaved the sn-2 acyl chain of PC by the use of phospholipase A2, and 
then coupled the resulting alcohol to an azide or alkyne-terminated fatty acid. Following 
this, click chemistry was used to join two of these PC analogs via the use of diazido or 
dialkynyl linkers to produce bolaamphiphiles of the type seen in Figure 1.8. 
Unfortunately, these compounds did not form stable membranes, presumably because 
of the polar triazoles formed from the double click reaction, which must reside in the 




Figure 1.8. Types of bolaamphiphiles generated by Smith and co-workers.124 
Smith and co-workers have also reported the synthesis of PS probes containing 
an alkyne at the sn-2 terminal end seen in Figure 1.9.125 Again using a chemoenzymatic 
approach, a PC derivative was hydrolyzed by phospholipase D (PLD) to form a PA 
analog, which was then reacted with a protected serine and subsequently deprotected. 
These PS probes were then derivatized via click chemistry to azide-containing 
fluorophores, and they have recently been reported for their use in labeling mammalian 
cells.126 The PS derivatives in this report containing a neutral coumarin or NBD 
fluorophore are shown to cross cellular membranes and participate in flippase activity, 
while the use of a charged fluorophore such as carboxyfluorescein does not cross 
cellular membranes nor participate in flippase activity.  
An example by Schultz and co-workers used phosphatidic acid (PA) probes 
containing click functional groups in the lipid tails.127 These lipid probes were protected 




























and is then cleaved inside cells to yield the active PA probe. These probes were used to 
label and detect PA in cells, but they discovered that the copper required for the click 
chemistry is toxic to cells and therefore the cells must be fixed prior to labeling. To 
circumvent the problem of having to fix cells, Schultz also exploited copper-free click 
chemistry by incorporating a cyclooctyne in the tail of a PA probe seen in Figure 1.9. In 
this example, they were able to visualize labeling in live cells by clicking on a coumarin 
azide. They detected no cytotoxicity and noted that mitosis continued to occur post-
labeling. 
 
Figure 1.9. Lipid probes containing click moieties in the acyl chains.125-127 
Our group has also exploited click chemistry to synthesize lipid probes.5,128-131 
Matt Smith of our group has used a modular approach for synthesizing click derived 
analogs of diacylglycerol (DAG) and phosphatidic acid (PA) seen in Figure 1.10, and 
through that discovered that such modifications do not have a great affect on the protein 
binding affinity of those signaling lipids.130,131 Meng Rowland of our group used PIPn 
photoaffinity probes to characterize novel PIPn binding proteins through the use of 
activity based protein profiling (ABPP).128 The synthetic probes contained an azide or 



























detection, or a biotin moiety as a purification handle. The biotin was chosen because it 
as a well-documented affinity for avidin and has been used for a wide array of 
applications where a strong and sometimes reversible reaction is needed.14,38,128,132 Our 
group has also used biotin as an immobilization anchor for attaching whole liposomes to 
a microplate surface to then be used for protein–binding studies.129  
 
Figure 1.10. Types of DAG and PA probes generated by our lab which contain a modification at 































Chapter 2: Microarray Analysis of Protein Binding Employing 
Synthetic Biotinylated Analogs of the Phosphoinositides  
2.1 Background and Significance 
The phosphatidylinositol polyphosphates, or phosphoinositides, are a family of 
compounds that are of great importance within signaling lipids.4,133,134 Like other 
signaling lipids, the phosphoinositides act as ligands in the recruitment of peripheral 
proteins to membrane surfaces, which regulates protein function and subcellular 
localization.1 These events are especially important because of their ability to transmit 
information from the membrane into signaling cascades and since defects in these lipid 
signaling events have been linked to diseases including diabetes and cancer.2,133,135,136  
2.1.1 Lipid–Binding Domains and Important Pathways 
The phosphoinositides are known to bind an ever-expanding list of cellular 
proteins, and there are a wide range of phosphoinositide–binding domains present 
within those proteins including PH, PX, FYVE, ENTH, ANTH, FERM, Tubby, and 
PROPPIN domains.4 Among these, there is great diversity in the binding affinities and 
specificities for each of the seven phosphoinositides. In the PH domain family alone, 
there are over 250 members reported, with very few being fully characterized, and only 
about 15% of those bind the phosphoinositides with high affinity.1,4 It is imperative to 
discover and characterize the various PIPn–binding proteins because of their great 
importance in numerous cellular processes and disease relations. This has previously 
been hampered by the difficult synthesis of the PIPn isomers and lack of an appropriate 
method for screening a large number and wide variety of proteins.  
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The structural complexity of the phosphoinositides complicates probe synthesis, as 
these phospholipids consist of phosphodiester-linked myo-inositol headgroups that are 
phosphorylated at every combination of the 3-, 4-, and 5- positions, generating seven 
naturally occurring isomers that are represented in Figure 2.1. While complex, a number 
of successful syntheses have been reported which use protecting group chemistry to 
achieve the enantioselectivity and regioselectivity required to access each isomer.137-148 
There have also been reports by Miller and co-workers of stereoselective 
phosphorylation of myo-inositol substrates using peptide catalysis.149-153 These 
strategies have led to successful probe generation and characterization of protein–
binding, but require complex synthesis for each reporter probe that therefore limits their 
broad applicability.  
 





























































2.1.2 Effective Strategies for Studying Protein–PIPn Binding  
Due to the complex nature of protein–PIPn binding interactions, model systems 
are typically implemented to elucidate the details of binding at the molecular level. As 
discussed in Chapter 1, a number of effective strategies for characterizing protein–lipid 
binding have been developed, including SPR analysis employing both membrane and 
individual lipid motifs, fluorescence, monolayer penetration, vesicle pelleting, monolayer 
penetration assays, and calorimetry.16,20 In addition, creative approaches for generating 
PIPn-presenting materials have been reported, such as solid supports that have been 
used for affinity purification of target proteins, polymerized liposomes, and 
dendrimers.154-166  
As mentioned, the SPR assay works by immobilizing whole liposomes onto the 
sensor chip, which is then used for detecting binding and determination of kinetics of the 
ligand–protein complex formation. Our group has also used whole liposome 
immobilization as a means of detecting protein binding to DAG though anchoring 
liposomes to a streptavidin-coated surface via the incorporation of a biotinylated lipid.129 
A similar immobilization approach via biotin-avidin has been used by Gilchrist and co-
workers, but it has not yet been used for assessing protein–binding.167  
Meunier and co-workers reported the use of avidin-coated beads to immobilize 
PI(4,5)P2-biotin derivatives that were then used to pull down protein effectors from 
chromaffin granules.161 After incubation of the PIP-beads with the protein solutions, the 
protein solutions were separated by SDS-PAGE and visualized by Coomassie blue 
staining. The bands of interest were excised, subjected to in-gel trypsin digestion, and 
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mass spectrometry analysis. Using this method, they identified the following proteins of 
interest: β-spectrin, α2-spectrin, α-adaptin, synaptotagmin-like protein 4, synaptotagmin 
1, and synaptotagmin 7. Using the same methodology, Painter and co-workers used a 
biotinylated PI(3,5)P2 immobilized onto neutravidin beads to pull down binding proteins 
from the cytosolic extract of adrenal neurosecretory cells.154 Specifically, they report the 
elucidation of PI(3,5)P2–binding protein svp1p, a protein known to be involved in 
membrane trafficking, which was analyzed by SDS-PAGE and Western blotting. 
Ferguson and co-workers have used polymerized liposomes containing a single-
tailed PIPn isomer (PIP3, PI(4,5)P2, and PI(3,4)P2) to detect protein binding to PH-
domain bearing nitrocellulose membranes as their initial screening platform.164 In 
addition, they performed electrophoresis, Alphascreen binding and competition, and 
SPR analysis, which complemented previous results using NMR, dot-blots, and affinity 
resin analyses of the RAG2 protein.168  
Additionally, PIPn–protein affinity and multivalency has been studied by Oakley 
and co-workers through the use of dendrimers displaying multiple PI(4,5)P2 
headgroups.165,166,169 In these reports, polyamidoamine (PAMAM) was used as a core to 
build out a dendrimer through reaction with 3,4-diethoxy-3-cyclobutene-1,2-dione, which 
was then reacted with an amine terminated PI(4,5)P2. While their first two reports 
focused more on the characterization of these dendrimers, the most recent report uses 
these dendrimers to investigate the multivalent nature of PI(4,5)P2–profilin binding. In 
this report, they used fourth generation PAMAM dendrimers to assess the protein 
binding because it is expected that they closely resemble micelles in their size and 
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headgroup spacing and each dendrimer displays approximately 46 PI(4,5)P2 
headgroups. These PI(4,5)P2 dendrimers were then used to assess profilin binding 
through ELISA (enzyme-linked immunosorbent assay), which resulted in determining 
the stoichiometry for PIP2–profiln binding is ~6:1 when using the PIP2 dendrimers. This 
result is higher than they observed for profilin binding to PIP2 liposomes, which may 
indicate that the micelles are too small to accommodate more protein associations. 
Nevertheless, their binding stoichiometry is in line with previous reports indicating 5-10 
PIP2s per profilin.170-175 
The previously discussed PIPn–binding assays have afforded advantageous 
information regarding lipid binding, but they each have disadvantages as well. Many of 
the assays discussed require expensive instrumentation and the detection may be 
limited to a very specific system, not allowing for rapid quantification of binding partners 
as in a high-throughput system. In addition, many of these systems are using simplified 
model membrane systems, but it would be advantageous to study binding in various 
contexts that mimic different aspects of the cell membrane.  
Carbohydrate–protein binding has been studied using surface-based techniques 
for analyzing recognition, which mirrors certain protein–lipid binding events.106,176-180 
Microarray analysis has proven advantageous for studying the interactions of these 
carbohydrate systems and has been used to address ligand specificities and structural 
requirements for recognition among various receptors. These microarray methods have 
also been used to probe the effect that multivalency has on protein affinity by controlling 
the carbohydrate density on the surface and for characterizing receptor variations 
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associated with disease using cell extracts. Since many of these same activities of lipids 
and their receptors are not well understood and are similar to carbohydrate–protein 
binding, we sought to exploit the advantages of microarray to apply to lipid binding 
events. We desired to develop a surface-based platform to rapidly analyze protein–PIPn 
binding capable of employing all seven natural isomers. 
There is a need to examine the protein–binding partners of the 
phosphoinositides, but a layer of complexity is added because of the lipid membrane in 
which they typically exist. There are proteins that bind the PIPns that are known to 
require the membrane environment, while others bind preferentially to the 
headgroup.17,134,181-188 For instance, based on the crystal structures of certain PH 
binding domains, it seems to have a binding pocket to accommodate the 
phosphorylated myo-inositol moiety, which points to strong headgroup association. 
Because of this evidence, we began our search using the isolated PIPn headgroups and 
members of the PH domain family.  
A prominent and heavily studied member of the family of proteins that contain PH 
domains is Akt, also known as protein kinase B (PKB), because its dysregulation is 
associated with many cancers such as breast, colon, ovarian, pancreatic, lymphoid, and 
prostate.2,189-195 Beginning with PI(4,5)P2, phosphoinositide 3-kinase (PI 3-K) 
phosphorylates the 3-position to form PI(3,4,5)P3, which then recruits Akt to the 
membrane surface, where it is activated through multiple posttranslational 
phosphorylation events.196 Akt then feeds into a number of pathways that control cell 
proliferation, apoptosis, and growth. The actions of PI 3-K are opposed by the 3-
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phosphatase PTEN, whereby PTEN dephosphorylates the 3-position reforming 
PI(4,5)P2. These enzymes that produce and modify PIP3, PI 3-K and PTEN, are among 
the most heavily mutated oncoproteins, and tumor suppressors in cancer.197-199  
 
Figure 2.2. Akt binds PIP3, which is generated by phosphorylation of PIP2 by PI-3K. Activated Akt 
regulates many downstream pathways including cell proliferation. This is an important protein–
lipid binding pathway as the over-stimulation of Akt results in disease. 
2.1.3 Previous Protein–Binding Results 
We chose to exploit a surface-based immobilization strategy because it is a rapid 
and high-throughput platform for studying the interactions of various proteins with all 
seven phosphoinositide isomers. Using biotinylated analogs of the PIPns, our group has 
developed a method for detecting the binding of various proteins to the PIPns. Our 
assay uses antibody-based detection, which provides a major advantage because it is 
amenable to detecting a variety of specific target proteins using the biotinylated probes 


























We first detected the binding of the PH domain of β-spectrin to PI(4,5)P2 
following the scheme outlined in Figure 2.3.134,200 The PI(4,5)P2–biotin analog 2.19 was 
immobilized onto a streptavidin coated 96-well microplate by placing a solution of the 
PI(4,5)P2 of a known concentration into each well and incubating at room temperature. 
Following washes to remove unbound probe, a solution of the GST-tagged PH domain 
of β-spectrin was added to each well and incubated. Then the microplate was washed 
and, to each well, horseradish peroxidase (HRP)-tagged anti-GST antibody was added, 
incubated, and the wells were thoroughly washed. Finally, enzyme-based 
chemiluminescence detection was used to determine the amount of protein bound to 
the PI(4,5)P2–biotin ligand. The luminescence results were averaged and plotted versus 
probe concentration. The results of the β-spectrin PH domain binding are shown in 
Figure 2.4, which shows a single site saturation curve, as expected. The Kd,surf of β-
spectrin PH domain was found to be 6 ± 3 nM using this strategy.201 
Previous to this assay, the binding of the PH domain of β-spectrin was studied by 
a surface plasmon resonance (SPR) assay and yielded a Kd of 125 ± 18 nM.201 In this 
study, the entire PI(4,5)P2 lipid was used and incorporated into liposomes, so it is not 
unexpected that the value reported by using the isolated lipid headgroup differs. In a 
membrane environment, the clustering and presentation of the lipid headgroup will be 
different from a surface immobilized lipid headgroup, and therefore, it is perhaps not 
surprising that the binding affinity is not equivalent. In this assay, we have termed our 
dissociation constant Kd,surf to acknowledge the differences in membrane and surface 
affinities, following the example of Wong and co-workers.176 The PH domain of other 
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proteins, specifically Btk, GAP1, and Grp1, have been studied with the soluble 
Ins(1,3,4,5)P4, the cleaved PIP3 headgroup.17,202,203 In an ITC assay using Grp1, a PH-
domain-containing protein, a Kd value of 27.3 nM is reported, which is similar to that 
seen in our surface-based assay.17  
 




































Figure 2.4. Binding results of β-spectrin and PI(4,5)P2 2.20 based on the immobilization and 
chemiluminescence assay performed. 
2.2 Probe Design 
Following initial successful results in lipid microplate analysis, we set out to 
access all seven isomers of the phosphoinositides from common intermediates and 
design them in such a way that multiple analogs could be accessed for varying 
applications. In short, we wanted to be able to identify new protein binding partners as 
well as quantify the binding affinity of known receptors.  
In the natural PIPns, the myo-inositol is connected via a phosphodiester linkage 
to the glycerolipid backbone, as shown in Figure 2.1, yet it has been shown that the lipid 
backbone is not always required to achieve protein binding.4,134 Utilizing this knowledge, 
we designed our lipid probes to contain a small hydrophobic linker to potentially mimic 
the glycerolipid backbone while simplifying synthetic access as well as the attachment 
of reporter groups. We chose to append this short hydrocarbon chain, but instead of the 
typical methyl group at the terminal end, we desired an amine for easy conversion into 








































































desired probes, following an example set forth by Prestwich and co-workers.204-212 The 
structures of our amino-tagged PIPn analogs are shown in Figure 2.5. For the 
microarray immobilization assays we wanted to perform, we chose a biotin appendage 
because of its well-documented affinity for avidin and proven usage in surface-based 
immobilization assays.129,200,213 The final feature of our probes is the tetraethylene glycol 
(TEG) linker to space the headgroup from the biotin and surface of the plate. We chose 
TEG as a water-soluble linker to ensure that the headgroup would be properly 
presented as erect, rather than laid horizontally on the surface. Recently, Iyer and co-
workers showed that a long tether is critical in studies employing the decoration of 
streptavidin-coated microplates, as the systematic shortening of this linker led to drastic 
reductions in binding.214 Having formulated the design of these probes, we set out to 
plan the synthesis for achieving them. We wanted our synthetic route to include a final 
global deprotection step to avoid complicated purification of the highly polar resulting 
phosphoinositides. Therefore, all of the protecting groups in the next to last step, 
compound 2.18, had to be compatible with deprotection via hydrogenation, a clean 



































































































2.3 PI(3,4,5)P3 Probe Synthesis 
In order to synthesize these analogs, we followed the groundwork laid by Bruzik 
and co-workers and synthesized the amine version of all seven PIPn isomers beginning 
with myo-inositol.139,215-217 Taking advantage of the inherent nature of the myo-inositol 
and choosing proper protecting groups has allowed us to synthesize all isomers in good 
yield with high selectivity. Figure 2.6 shows my role in synthesizing PI(3,4,5)P3 isomer, 
which begins by appending (+)-camphor to the 2- and 3- positions of the myo-inositol 
and performing a chiral resolution via recrystalization.217 Beginning with the meso 
compound, myo-inositol has five of the six hydroxyls in an equatorial position in its most 
stable conformation, with only the 2-position being axial.  Because of this axial hydroxyl, 
the (+)-camphor preferentially protects the 1-2 and the 2-3 hydroxyls, creating 
diastereomers that can then be separated by recrystallization. Once the appropriate 
isomer 2.8 was collected, as determined by its optical purity in comparison to literature, 
the next step was to protect the 1-position using tert-butyldiphenylsilyl chloride 
(TBDPSCl) in the presence of imidazole and pyridine to yield 2.9. Next, the 4- and 5-
positions were protected with benzoyl groups (Bz) to produce compound 2.10 and the 







































































































































































At this point, the resulting triol 2.11 was used to synthesize both the 4,5- and 
3,4,5- analogs, with only a step difference. To generate the 3,4,5-isomer, by using the 
bulky nature of the TBDPS group to our advantage, we were able to install a third 
benzoyl group on the 3-position creating 3,4,5-benzoyl protected diol 2.12. The 
available alcohols of 2.12 were then protected using benzyloxymethyl chloride (BOMCl), 
followed by deprotection of the benzoyl groups to generate compound 2.14. The 
deprotection of these hydroxyls proved to be somewhat problematic when following 
methods that were effective for the synthesis of the other PIPn isomers, such as sodium 
methoxide in methanol, as the starting material was minimally soluble in methanol. The 
addition of methylene chloride yielded small amounts of product, but when the reaction 
scale was increased, the yields declined dramatically. The use of an aqueous solution 
of sodium hydroxide with methanol and methylene chloride was chosen as a 
dependable method for generating triol 2.14 on both large and small scale. This triol 
was then reacted with dibenzyldiisopropyl phosphoramidite in the presence of 1H-
tetrazole and then oxidized with meta-chloroperoxybenzoic acid (m-CPBA) to give the 
protected phosphotriesters of compound 2.15. Subsequently, the TBDPS protecting 
group was removed, and more phosphoramidite chemistry installed the 
benzyloxycarbonyl (Cbz) protected amine tail onto the 1-position to yield the fully 
protected headgroup 2.18. The final step to afford the fully deprotected PI(3,4,5)P3 
involved a global deprotection with palladium on carbon and hydrogen gas, resulting in 
pure product. This route minimizes challenges in the purification of the deprotected 
compound, which is very polar and can cause purification problems. With the amine 
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version of all seven PIPns in hand, we set out to make functionalized derivatives. Our 
lab has made various probes of the PIPns that have been used for a wide array of 
applications, but the probe 2.19, seen in Figure 2.8, containing a biotin tag is the 
molecule of interest here, which was synthesized by Meng Rowland.5,128,200,213,215 
Following our initial success, we extended our microarray platform technology to 
detect Akt binding to each of the PIPns.213 Using the purified GST-tagged PH domain of 
Akt, we performed similar immobilization and protein binding experiments using all 
seven PIPn isomers. This approach is advantageous because it can rapidly quantify 
which isomers are the strongest binders of any protein of choice. The biotinylated 
headgroups of all seven of the PIPns were immobilized in a streptavidin plate as 
described previously. The wells were then washed and incubated with a constant 
concentration of GST-tagged Akt PH-domain. After sufficient washing, the ligand–
protein binding was then quantified via chemiluminescence and the results are shown in 
Figure 2.7. In agreement with previous reports, it is shown that PI(3,4,5)P3 and 
PI(3,4)P2 are the strongest binders of Akt, while the remaining PIPns do not yield any 




Figure 2.7. Binding curves obtained from a microplate-based immobilization assay of all seven 
biotinylated PIPns with Akt-PH.213 
2.4 Results and Discussion 
While we have achieved success in detecting protein binding to the PIPns in 
microplates using β-spectrin and PI(4,5)P2 and Akt-PH and all seven PIPns, this 
technique requires an appreciable amount of ligand, protein, and antibodies, which are 
all rather costly. We desired to miniaturize the entire experiment and decided true 
microarray was an excellent way to accomplish this.  
2.4.1 Microarray Analysis of Akt-PH Domain with Biotinylated PIP3 
Microarray generally employs a glass slide that can be derivatized with a variety 
of groups for immobilizing a number of ligands with various functional tags. These glass 
slides measure 25 mm X 75 mm and thousands of experiments can be performed on a 
single slide, greatly minimizing the amount of ligand, protein, and antibodies required. In 
these experiments, we have employed an avidin coated slide for use with the same 
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PIPn-biotin analogs that were used in the previous assays. We began by trying to repeat 
the microplate Akt-PH binding experiment using the microarray technology. Because of 
the mobility of the luminescent substrate, fluorescence detection is needed when 
working with glass slides, so the HRP-tagged antibody was exchanged for a primary 
and secondary antibody system using rabbit anti-GST and a fluorescent cyanine-3 
(Cy3) labeled goat anti-rabbit IgG (Figure 2.8). We began with PI(3,4,5)P3 as our only 
ligand because it is known as the strongest binder of Akt out of the seven PIPns, which 
is also seen in our previous results.182,213 Using avidin-coated glass slides, the 
PI(3,4,5)P3–biotin 2.19 was printed using a robotic pin printing system, which can be 
seen in Figure 2.9. The pin dips into the solution prepared in a 96-well plate, blots onto 
a blank slide, and then prints the compound onto the avidin-coated slide the desired 
number of times depositing ~0.6 femtoliters of sample creating a spot diameter of ~50 
µm. Each sample is typically spotted in 20 replicates, resulting in two grids with 10 spots 




Figure 2.8. Cartoon depiction of the fluorescence based assay performed via microarray on glass 
slides. 
  
Figure 2.9. Left: image of a robotic pin printer containing 32 pins. Right: Close up image of a pin 
and the channel that holds the solution while printing.  
Beginning with printing a grid where every row and column has PI(3,4,5)P3–biotin 
in the same concentration (500 µM) and subjecting the resulting surface to the assay 



































from the image, there are variations in spot diameter and intensities as you go down the 
columns, despite the fact that the PI(3,4,5)P3-biotin was immobilized at a constant 
concentration, which is a common technical challenge in microarray analysis. The 
column averages, standard error, and percent error in fluorescence counts for this 
uniform concentration grid are outlined in Table 2.1. There are several possible reasons 
for this non-uniformity, such as variations in the density of the reactive functional groups 
on the slides, the numerous steps that are required for the assay, and variations in the 
efficacy of pin printing at different locations. In this case, it can be attributed to 
inconsistencies in the robotic pin printing because, as seen in the image, the effect 
seems to be most prominent in the lower right of the grid, which corresponds to the 
spots printed later in the printing sequence. To try and remedy this, shorter print 
sequences were run and the pin was washed between each printed grid. Overall, the 
image shows relatively uniform fluorescence, despite the spot morphology differences, 
providing evidence that our assay worked as expected.  
  
Figure 2.10. Results of Akt-PH binding via microarray assay. Left: Fluorescent image obtained by 
printing constant concentration of PIP3-biotin 2.19. Right: Graphed results of mean fluorescence 
intensity of each column on the left with error bars depicting the standard error. 
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tic reductions in binding (Lewallen et al., 2009). Finally, the biotin371
moiety of 1c is employed for high-affinity non-covalent immobi-372
lization of these ligands onto streptavidin-coated microplates in an373
effort to avoid non-specific binding interactions.374
To develop an assay for characterizing binding specificity, we375
set out to extend our previous approach to produce the corre-376
sponding analogs of all seven naturally occurring PIPn isomers377
(1a–g). With regard to synthesis, we have taken advantage of378
previously successful strategies for inositol polyphosphate and379
PIPn probe development using modular scaffolds bearing a reac-380
tive moiety that can be derivatized in the final step of synthesis381
for convenient access to diverse structures (Dorman et al., 1995;382
Henne et al., 1988; Inoue et al., 1999; Marecek et al., 1992;383
Nakanishi et al., 2002; Olszewski et al., 1995; Prestwich et al.,384
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(Conway et al., 2010; Painter et al., 1999). To synthesize ligands393
for binding analysis using all isomers, 2a–g were allowed to react 394
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since few binding studies have been reported using all PIPn iso- 404
mers. GST-tagged Akt-PH was expressed and purified as described 405
previously (Manna et al., 2007). In the assay, compounds 1a–g 406
were immobilized in separate rows of streptavidin-coated 96-well 407
microplates by incubating with solutions with optimized concen- 408
trations, typically 500 nM (Scheme 2). Each isomer was then treated 409
with varying concentrations of GST-tagged Akt-PH, followed by 410
detection via chemiluminescence-based ELISA signal transduction 411
using an HRP-tagged anti-GST antibody. Each step of the assay was 412
followed by washes to remove any unbound species. 413
The results from this approach are shown in Fig. 1. Here, the 414
analogs corresponding to PI(3,4,5)P3 (1a) and PI(3,4)P2 (1b) yielded 415








































1 3539851 3.28 7.42 
2 4046026 6.09 5.82 
3 3968459 3.47 3.79 
4 3989071 6.55 4.33 
5 3948771 5.41 3.27 
6 3964619 7.24 3.69 
7 3833509 5.01 0.26 
8 3776627 6.83 1.23 
9 3915266 7.40 2.40 
10 3769995 8.67 1.40 
11 3469492 3.74 9.26 
12 3661295 5.62 4.24 
average 3823582 5.78 3.93 
 
Following these initial results, a grid of non-uniform concentration was printed, 
where the leftmost column contains only buffer and the rightmost has the highest 
concentration of PI(3,4,5)P3–biotin at 500 µM. The fluorescent image obtained from this 
can be seen in the left panel of Figure 2.11. The spot morphology of this grid seems to 
be improved from previous, but it is still imperfect. The plot of fluorescence versus 
ligand concentration from this image shows a signal increase as the concentration of 
the ligand increases. In the microplate assays, the highest concentration of ligand was 
500 nM, whereas with the microarray technology, to see an appreciable signal, we had 
to probe much larger concentrations (up to 500 µM). This could be attributed to the 
detection limit in microplates because of the higher sensitivity of the chemiluminescence 
over fluorescence. While we have achieved these initial results, the microarray 
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techniques still requires further optimization. A further discussion of some of the 
problems associated with microarray can be found in Section 2.7. 
     
Figure 2.11. Results of Akt-PH binding via microarray assay. Left: Fluorescent image obtained by 
printing varied concentration of PIP3-biotin 2.19. Right: Graphed results of mean fluorescence 
intensity of each column on the left with the error bars depicting the standard error. 
 
2.5 Probing the Affects of Multivalency on Protein-Lipid Binding 
While Akt is of immense importance, there is a great need to study the 
interactions of lipids with multivalent proteins. A protein is classified as multivalent if it 
can simultaneously bind multiple ligands. In multivalent systems, two typical responses 
are observed based on the amount and clustering of the ligand on the surface, a 
threshold or a gradient. A threshold response is essentially an on-off switch in that 
minimal binding occurs until some threshold is reached, which turns on binding and an 
immediate response is observed. A gradient response is the result of a linear 
relationship in that as the ligand density is increased, the binding affinity is gradually 
enhanced as well. 
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Multivalent carbohydrate binding has been heavily studied, and it has provided 
great insight into how multivalency affects carbohydrate binding.176,221 Surface-based 
techniques are especially advantageous for carbohydrates and signaling lipids because 
these ligands are typically displayed on the membrane surfaces and it is in that native 
environment that they are able to bind soluble proteins. Wong and co-workers have 
successfully used microarray to study carbohydrate–lectin binding.106,176,177,221,222 Using 
four ligands composed of differing numbers of mannose units, his lab probed the 
binding of concanavalin A, two other mannose binding lectins, lens culinaris agglutinin 
(LCA) and pisum sativum agglutinin (PSA), and the human monoclonal antibody 
2G12.176 Based on those results, it is expected that the PIPns will behave similarly and 
analysis of multivalent PIPn–binding proteins will benefit from a similar surface-based 
strategy, but it should be noted that profilin has more binding domains than lectin.  
Wong and co-workers have also used dendrimers composed of mannose to 
study carbohydrate–protein binding to the human monoclonal antibody 2G12.223 As 
previously mentioned, the use of dendrimers has also proven effective for studying the 
multivalent binding of PI(4,5)P2 to profilin by Oakley and co-workers.166 While they have 
been effective at probing protein binding, dendrimers require difficult synthesis often 
resulting in minimal product, complex assay conditions that often uses expensive 
instrumentation, and provide minimal control over ligand density, so we decided that the 
surface-based immobilization microarray strategy would be an effective one for studying 
many multivalent protein interactions with the phosphoinositides. A surface-based 
strategy also affords us control over the surface density of the ligand, a beneficial factor 
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when exploring multivalent effects. We modeled our multivalent microarray studies after 
the previously described systems of Wong and co-workers and began by evaluating 
profilin, a documented binder of PI(4,5)P2. In order to probe multivalent protein binding, 
the microarray assay must be performed with numerous grids of varying ligand 
concentration that are then incubated with several protein concentrations. Microarray 
serves as a beneficial technique for these experiments because the same ligand 
solutions can be printed onto one glass slide many times to create numerous grids that 
can all be incubated individually with numerous protein concentrations. From a single 
successful microarray assay, the Kd,surf of many protein concentrations can be 
determined, providing essential evidence for how multivalency affects protein–lipid 
binding.  
 
2.6 Profilin Microarray 
It is known that profilin preferentially binds PI(4,5)P2 over any other PIPn isomer, 
so in these microarray experiments the biotin analog of PI(4,5)P2 has been used, 
compound 2.20.166 In order to probe the multivalency, using experiments similar to 
those performed by Wong and co-workers for multivalent carbohydrate binding, we 
desired to print multiple grids with varying concentrations of PI(4,5)P2 and then incubate 
those grids with varying amounts of profilin. Based on the Kds determined by curve-
fitting the plot of fluorescence versus protein concentration for each PI(4,5)P2 
concentration, one can determine the extent to which multivalency affects profilin 
binding. The best results to date are shown in Figure 2.12, where the PI(4,5)P2-biotin is 
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printed in increasing concentration (0–400 µM) from left to right in each 12x10 grid, and 
each set of 4 grids is incubated with increasing profilin concentration (3 nM, 30 nM, 300 
nM, and 3 µM). The results show moderately what is expected in that as the 
concentration of profilin increases, so does the fluorescence. There also seems to be a 
general trend of increasing fluorescence from left to right across each grid, providing 
evidence that the higher concentration of ligand binds more profilin. However, these 
results are only preliminary, and these experiments still need to be further scrutinized 
and optimized to be used with a wide variety of proteins for eventual use in diagnostic 
studies.  
 
Figure 2.12. Best PIP2-profilin binding results to date where PIP2 concentration increases in each 
grid from left to right (0–400 uM) and profilin concentration increases from left to right for each set 











2.7 Problems with Microarray 
The two aforementioned microarray assays have yielded some initial results, but 
both could benefit from further optimization. One of the biggest problems with these 
assays is their consistency. Due to many variables, the actual printing of the ligand on 
the slide often proves to be temperamental. The buffer used to dissolve the solutions for 
printing is typically an aqueous solution with a high salt content. The salt serves a nice 
purpose of being able to visually see spots on the slide after the printing is finished. 
There are many instances where after running a print sequence, there are no visible 
spots on the slide. If this is the case, something has gone wrong in the actual slide 
printing. This could be caused by various issues but is most likely due to the solution 
that is being spotted evaporating on the pin tip. This evaporation can be addressed in 
many ways including increasing humidity of the environment while printing, adding 
solvents such as dimethylsulfoxide or glycerol to enhance the viscosity and printability 
of the solution, and decreasing the print time by adjusting the number of spots and grids 
printed from each dipping of the pin. Another important thing to note when printing 
slides is that the best grids result from printing ligands where the lowest concentration is 
printed first and the highest last. If the highest concentration of ligand is printed first, 
there are problems with the pin not washing properly and the higher ligand 
concentrations bleed over into the next row causing contamination.  
Once the printing process is dependable, there is a need to optimize the actual 
assay as well. Although we have achieved protein–binding results in microplates, there 
is not necessarily a direct relationship to the microarray assays. The protein 
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concentrations that have been used have resulted from educated guesses based on the 
microplate assays, but as discussed, the conditions that have been determined as 
optimal for microplates are not always directly correlated to the microarray assays. 
However, an advantage to microarray over microplate analysis is because so many 
experiments can be performed on a single microarray slide, many protein 
concentrations can be probed simultaneously. Although the amount of protein used is 
much lower than the microplate assays, this could benefit from further optimization to 
determine the ideal concentration window. In the profilin studies, several protein 
concentrations have been evaluated, including 3 nM, 30 nM, 300 nM, 3 µM, and 33 µM. 
The appropriate antibody concentrations have been minimally investigated, as the 
background signal resulting from too much antibody yielded undesirable results, and 
decreasing this concentration provided a more satisfactory result. The antibody 
concentrations that have been tested in both the Akt and profilin assays are 1/0.5 
µg/mL, 0.5/0.25 µg/mL, and 0.2/0.1 µg/mL. The incubation times and washing 
procedure were chosen based on literature examples and our previous microplate 
assays, but these could also benefit from further investigation. Incubation times have 
generally been 1 hour, but other times such as 2 hours, 4 hours, and even overnight 
have been used. The washing procedure seems to greatly affect the end results, as in 
one instance the overall assay yields good spots with minimal background signal, while 
other times, even when the same procedure is followed, the background is so high that 
no spots can be seen or the slide is completely black with no spots being detected. The 
protein concentration, antibody concentrations, washing procedure, and incubation 
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times are all part of the process that need to be further scrutinized to yield the best 
possible, dependable microarray assay that has a wide array of applications for many 
protein-binding studies.  
 
2.8 Experimental 
2.8.1 General Considerations 
Generally, reagents were purchased from Acros, Aldrich or Advanced ChemTech and 
used as received. Dry solvents were obtained from a Pure Solv solvent delivery system 
purchased from Innovative Technology, Inc. Column chromatography was performed 
using 230-400 mesh silica gel purchased from Sorbent Technologies and C18 (17%) 
reverse phase SPE columns (6 ml, 2 g) purchased from Silicycle. NMR spectra were 
obtained using a Varian Mercury 300 spectrometer, a Bruker Avance 400 spectrometer, 
and a Varian 500 spectrometer. Mass spectra were obtained with JEOL DART-
AccuTOF spectrometer and an ABI Voyager DE Pro MALDI spectrometer with high 
resolution capabilities. Optical rotation values were obtained using a Perkin-Elmer 241 
polarimeter. The GST-tagged PH domain of Akt was expressed and purified as 
previously described.219 Slide printing was performed using a VersArray ChipWriter Pro 
obtained from Bio-Rad Laboratories, Inc. (Hercules, CA). Fluorescence on slides was 
detected using a GenePix 4000B Micorarray Scanner. SuperAvidin coated slides were 
purchased from Arrayit Corporation (Sunnyvale, CA). The rabbit anti-GST antibody, Cy3 
conjugated goat anti-rabbit IgG antibody, anti-profilin antibody, and profilin were 
obtained from Novus Biologicals (Littleton, CO).  
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2.8.2 Synthetic Procedures  
1D-2,3-O-(D-1’,7’,7’-Trimethyl[2.2.1]bicyclohept-2’-ylidene)-myo-inositol (2.8): 
 
The following procedure was first described by Bruzik and co-workers217 whereby D-(+)-
camphor (32.6 g, 0.21 mol) was dissolved in methanol (35 mL) and 
trimethylorthoformate (165 mL) was added and stirred at rt for 48 hours after which 
sodium methoxide (685 mg) was added. The resulting solution was stirred at rt for 15 
minutes, and subsequently concentrated. The remaining residue was dissolved in 
toluene, filtered, and concentrated once more. The resulting residue was then dissolved 
in dimethyl sulfoxide (DMSO, 184 mL). To this solution was added myo-inositol (16.86 
g, 0.09 mol), and concentrated sulfuric acid (H2SO4, 0.95 mL) and the reaction was 
stirred at 75 °C for 3 h. After the allotted time, triethylamine (Et3N, 6.3 mL) was added. 
After 20 minutes of stirring, the mixture was then vacuum distilled at 80 °C after which a 
dark, sticky residue remained. The residue was brought to a weight of approximately 85 
g by adding DMSO. Chlororform (CHCl3, 285 mL), methanol (MeOH, 17.9 mL), water 
(5.7 mL), and para-toluene sulfonic acid (p-TsOH, 63 mg) were added, and the resulting 


















Büchner funnel and washed with 400 mL CHCl3 to give the crude product of 
diastereomers as a white solid cake. This resulting solid was recrystallized by dissolving 
in hot, refluxing methanol (1.6 L) containing 0.1% triethylamine. The solution was 
filtered while hot, the volume of solution was reduced by half, then cooled to rt, and 
finally placed in the freezer. After 2 days, the resulting crystals were collected (22.2 g), 
and recrystallized once more to afford compound 2.8 (8 g, 27%).  





The following procedure was first described by Bruzik and co-workers217 whereby 
protected myo-inositol 2.8 (3.5  g, 11.12  mmol) was dissolved in pyridine (35 mL) and 
imidazole (1.06 g, 15.57 mmol) was added. The mixture was placed under nitrogen, 
cooled to -10 °C, and tert-butyldiphenylsilyl chloride (TBDPSCl, 2.9 mL, 11.12 mmol) 
was slowly added. The reaction was allowed to warm to 4 °C and stirred overnight. The 
resulting mixture was concentrated and the residue purified via chromatography on 
















Characterizations matched previous reports.217 [α]D296 K = -25.2 (c = 4.4, CHCl3). 1H NMR 
(300 MHz, CDCl3): δ = 7.75 (dt, J = 5.8, 2.0 Hz, 4H), 7.36 (t, J = 6.2 Hz, 6H), 4.34 (s, 
1H), 3.87–3.70 (m, 3H), 3.59–3.39 (m, 2H), 3.09 (t, J = 9.3 Hz, 1H), 1.90 (t, J = 10.0 Hz, 
1H), 1.63 (d, J = 10.5 Hz, 3H), 1.36–0.99 (m, 15H), 0.84 (s, 3H), 0.78 (s, 3H) ppm. 13C 
NMR (75 MHz, CDCl3): δ = 136.27, 135.80, 133.80, 133.30, 127.60, 127.56, 127.41, 
123.79, 117.74, 76.88, 76.30, 75.93, 75.75, 73.11, 72.46, 72.27, 51.44, 51.26, 47.91, 





The following procedure was first described by Bruzik and co-workers139 whereby triol 
2.9 (409 mg, 0.74 mmol) was dissolved in pyridine (4.1 mL) and dichloromethane 
(CH2Cl2, 820 µL) was added. The reaction was placed under nitrogen, cooled to -40 °C, 
and benzoyl chloride (BzCl, 213 µL, 1.85 mmol) was added dropwise. The mixture was 
allowed to warm to rt and stirred for 3.5 h. The reaction was concentrated and the 
residue was extracted from water with dichloromethane (2 x 50 mL), and the organic 
















residue was purified via column chromatography on silica (5 – 20% acetone/hexane) to 
give 2.10 (422 mg, 75%) as a white foam.  
Characterizations matched previous reports.139 1H NMR (300 MHz, CDCl3): δ = 7.95 (d, 
J = 8.3 Hz, 2H), 7.83 (d, J = 9.0 Hz, 4H), 7.71 (d, J = 7.9 Hz, 2H), 7.52–7.20 (m, 12H), 
5.64 (t, J = 8.0 Hz, 1H), 5.14 (t, J = 8.7 Hz, 1H), 4.22 (t, J = 8.5 Hz, 1H), 4.13–3.99 (m, 
3H), 1.97–1.59 (m, 5H), 1.48–1.23 (m, 3H), 1.19–1.08 (m, 18H), 0.90 (s, 3H) ppm. 13C 
NMR (75 MHz, CDCl3): δ = 166.30, 165.28, 136.09, 135.85, 133.12, 132.93, 130.14, 
130.04, 130.00, 129.84, 129.67, 129.49, 129.31, 128.43, 128.24, 128.19, 127.91, 
127.74, 118.50, 73.39, 72.23, 71.58, 51.80, 48.05, 45.14, 44.46, 29.40, 26.98, 26.90, 




Protected myo-inositol 2.10 (5.41 g, 7.11 mmol) was dissolved in chloroform (55 mL). 
Water (355 µL) and trifluoroacetic acid (TFA, 6.75 mL) were added and the reaction 
mixture was allowed to stir at rt overnight. The following day, the reaction was 
















was then purified via chromatography on silica (15 – 50% acetone/hexane) to afford 
2.11 (4.16 g, 93%) as a white foam.  
Characterizations matched previous reports.139 1H NMR (300 MHz, CD3OD): δ = 7.87 
(dd, J = 16.1, 7.0 Hz, 8H), 7.50–7.21 (m, 12H), 5.73 (t, J = 10.0 Hz, 1H), 5.23 (t, J = 9.8 
Hz, 1H), 4.89 (s, 3H), 4.33 (t, J = 9.5 Hz, 1H), 3.88–3.72 (m, 2H), 3.50 (dd, J = 10.0, 2.5 
Hz, 1H), 1.13 (s, 9H) ppm. 13C NMR (75 MHz, CD3OD): δ = 167.62, 167.53, 137.33, 
137.04, 135.32, 134.41, 134.03, 131.02, 130.99, 130.81, 130.77, 130.50, 130.47, 





Triol 2.11 (211.5 mg, 0.337 mmol) was dissolved in anhydrous dichloromethane (4 mL), 
and triethylamine (142 µL, 1.01 mmol), and N, N’-dimethylaminopyridine (DMAP, 41.2 
mg, 0.337 mmol) were added. The reaction was placed under nitrogen, cooled to –40 
°C, and benzoyl chloride (BzCl, 58 µL, 0.51 mmol) was added dropwise. The mixture 
was allowed to warm to rt over 4 h and subsequently stirred at rt overnight. The reaction 
mixture was concentrated, dissolved in a solution of 35% acetone/hexane and filtered 


















Characterizations matched previous reports.217 1H NMR (300 MHz, CDCl3): δ = 7.97–
7.87 (m, 4H), 7.80–7.65 (m, 6H), 7.54–7.28 (m, 13H), 7.28–7.14 (m, 2H), 6.19 (t, J = 9.6 
Hz, 1H), 5.38 (t, J = 9.9 Hz, 1H), 5.16 (ddd, J = 10.5, 2.6, 1.2 Hz, 1H), 4.40 (t, J = 9.5 
Hz, 1H), 4.22 (s, 1H), 3.93–3.80 (m, 1H), 1.11 (s, 9H) ppm. 13C NMR (75 MHz, CDCl3): 
δ = 166.18, 165.65, 165.54, 135.87, 135.62, 133.26, 133.14, 132.95, 132.87, 132.29, 
130.34, 130.18, 129.81, 129.79, 129.51, 129.25, 129.10, 129.06, 128.34, 128.26, 
128.16, 128.09, 128.04, 74.54, 73.28, 72.19, 71.77, 70.56, 69.87, 26.98, 19.35 ppm. 
 
1D-3,4,5-O-Tribenzoyl-2,6-O-bis(benzyloxymethyl)-1-O-(tert-butyldiphenylsilyl)-
myo-inositol (2.13):  
 
Diisopropylethylamine (0.43 mL, 2.6 mmol) and benzyl chloromethyl ether (0.36 mL, 2.6 
mmol) were added to a solution of 2.12 (0.236 g, 0.323 mmol) in 1,2-dichloroethane (3 
mL). The reaction mixture was stirred at reflux for 24 h. After the reaction was finished, 
water was added and the mixture extracted with dichloromethane (2 × 50 mL). The 
combined organic phases were dried with magnesium sulfate, filtered and concentrated. 
The crude product was purified by chromatography on silica gel (hexane/acetone, 10:1) 
to yield 2.13 (0.158 g, 52%) as a syrup.  
[α]D296 K = +68.9 (c = 4.8, CHCl3). Other characterizations match previous reports.224 1H 

















10H), 7.29–7.09 (m, 11H), 7.05 (dd, J = 6.9, 2.6 Hz, 2H), 6.91 (dd, J = 6.5, 3.0 Hz, 2H), 
6.13 (t, J = 10.2 Hz, 1H), 5.58 (t, J = 9.6 Hz, 1H), 5.02 (d, J = 12.9 Hz, 1H), 4.92 (d, J = 
6.9 Hz, 1H), 4.80 (q, J = 6.5 Hz, 2H), 4.62–4.38 (m, 4H), 4.32–4.23 (m, 2H), 4.18 (d, J = 
12.3 Hz, 1H), 3.99 (s, 1H), 1.11 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3): δ = 165.88, 
165.77, 165.34, 137.69, 137.65, 135.92, 133.22, 132.99, 132.86, 132.81, 130.14, 
129.94, 129.71, 129.63, 129.54, 129.30, 129.12, 128.18, 128.09, 128.04, 127.85, 
127.40, 127.29, 127.21, 127.18, 96.74, 95.80, 72.53, 71.62, 71.00, 69.97, 69.63, 27.24, 
19.33 ppm. 
 
1D-2,6-O-Bis(benzyloxymethyl)-1-O-(tert-butyldiphenylsilyl)-myo-inositol (2.14):  
 
A 1% sodium hydroxide solution (2 mL) and dichloromethane (2 mL) were added to a 
solution of 2.13 (0.13 g, 0.134 mmol) in methanol (5 mL). The mixture was stirred at rt 
under nitrogen for 18 h. The solvent was removed and the residue purified by 
chromatography on silica gel (hexane/acetone, 4:1) to give 2.14 (0.66 g, 75%) as a 
syrup.  
[α]D296 K = +60.5 (c = 2.6, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.68 (t, J = 7.2 Hz, 4 
H), 7.45–7.25 (m, 16 H), 4.94 (d, J = 6.8 Hz, 1 H), 4.75–4.65 (m, 3 H), 4.54–4.51 (m, 3 
H), 4.42 (d, J = 11.6 Hz, 1 H), 4.30 (br. s, 1 H), 3.81–3.72 (m, 2 H), 3.66–3.54 (m, 3 H), 















= 136.3, 136.2, 135.4, 135.3, 133.1, 129.6, 129.3, 128.1, 127.6, 127.5, 127.3, 127.1, 
96.5, 96.2, 84.7, 82.6, 73.3, 72.2, 70.4, 70.0, 69.9, 26.5, 18.9 ppm. DART-HRMS: calcd. 
for C38H45O8Si [M – H]- 657.2884; found 657.2888. 
 
1D-2,6-O-Bis(benzyloxymethyl)-1-O-(tert-butyldiphenylsilyl)-myo-inositol 3,4,5-
Tris(dibenzyl phosphate) (2.15):  
 
Dibenzyl N,N-diisopropylphosphoramidite (0.40 mL, 1.22 mmol) was added to a solution 
of alcohol 2.14 (0.134 g, 0.203 mmol) and 1H-tetrazole (4.0 mL, 1.8 mmol, 0.45 M in 
acetonitrile) in dichloromethane (4 mL) under nitrogen, and the mixture was stirred at rt 
for 18 h. The reaction solution was cooled to –20 °C, and m-CPBA (0.315 g, 57– 86%) 
was added. The mixture was warmed to rt and stirred for 3 h. The solvent was removed 
and the residue purified by flash chromatography on silica gel (hexanes/acetone, 8:1) to 
access 2.15 (0.289 g, 99%) as a syrup.  
[α]D296 K = +15.5 (c = 2.6, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.76–7.67 (m, 4 H), 
7.38–7.05 (m, 46 H), 5.15–4.88 (m, 12 H), 4.83–4.64 (m, 7 H), 4.54–4.48 (m, 2 H), 
4.37–4.26 (m, 2 H), 4.08 (t, J = 12 Hz, 1 H), 3.98–3.91 (m, 2 H), 1.07 ppm. 13C NMR 
(100.6 MHz, CDCl3): δ = 138.2, 137.8, 136.2, 136.2, 136.1, 136.1, 136.0, 135.9, 135.9, 


































128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 128.0, 127.9, 127.9, 127.9, 127.8, 127.7, 
127.6, 127.4, 127.3, 96.6, 96.0, 75.1, 75.1, 75.1, 73.4, 70.7, 69.9, 69.6, 69.5, 69.5, 69.4, 
69.3, 69.2, 69.1, 69.0, 27.2, 19.4 ppm. 31P NMR (121.5 MHz, CDCl3): δ = 0.07, –0.04, –
0.28 ppm. MALDI-HRMS: calcd. for C80H85O17P3SiNa [M + Na]+ 1461.4666; found 
1461.4603. 
 
1D-2,6-O-Bis(benzyloxymethyl)-myo-inositol 3,4,5-Tris(dibenzyl phosphate) (2.16):  
 
A solution of fully protected inositol 2.15 (0.027 g, 0.019 mmol) in tetrahydrofuran (1 mL) 
was treated with tetrabutylammonium fluoride trihydrate (0.018 g, 0.056 mmol) and 
stirred at rt for 18 h. Following concentration, the residue was purified by 
chromatography on silica gel (hexanes/acetone, 3:1) to give alcohol 2.16 (0.019 g, 84%) 
as a syrup.  
[α] D296 K = –15.4 (c = 0.8, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.32–7.15 (m, 40 H), 
5.14–4.84 (m, 16 H), 4.70–4.60 (m, 5 H), 4.48–4.40 (m, 3 H), 4.28– 4.19 (m, 2 H), 3.85 
(t, J = 9.4 Hz, 1 H), 3.48–3.44 (m, 1 H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 137.6, 
136.9, 136.1, 136.0, 135.9, 135.9, 135.8, 135.7, 135.6, 135.6, 128.5, 128.4, 128.3, 
128.1, 128.1, 128.0, 128.0, 127.9, 127.8, 127.6, 97.1, 96.2, 82.4, 78.7, 76.8, 76.3, 75.4, 









































= –0.04, –0.48, –0.58 ppm. MALDI-HRMS: calcd. for C64H67O17P3Na [M + Na]+ 
1223.3489; found 1223.3498. 
 
Cbz-Aminohexanol Phosphoramidite (2.17):  
 
1H-Tetrazole (4.6 mL of a 0.45 M solution in acetonitrile, 2.07 mmol) and 1-(benzyloxy)-
N,N,N',N'-tetraisopropylphosphinediamine (1.392 g, 4.11 mmol) were added to a 
solution of Cbz-aminohexanol (0.694 g, 2.76 mmol) in dichloromethane (30 mL) under 
nitrogen. This mixture was stirred at rt for 2 h, at which point the solution was extracted 
with dichloromethane (3 × 80 mL) from saturated sodium hydrogen carbonate (80 mL). 
The combined organic phases were dried with magnesium sulfate, filtered, and 
concentrated, and the residue was purified by chromatography on silica gel 
(hexane/ethyl acetate/triethylamine, 100:10:1). The resulting colorless liquid 2.17 (0.983 
























inosit-1-yl Phosphate 3,4,5-Tris(dibenzyl phosphate) (2.18):  
 
Cbz-aminohexanol phosphoramidite 2.17 (0.183 g, 0.375 mmol) was added to a 
solution of alcohol 2.16 (0.180 g, 0.15 mmol), and 1H-tetrazole (1.0 mL, 0.45 mmol, 
0.45 M in acetonitrile) in dichloromethane (15 mL) under nitrogen, and the mixture was 
stirred at rt for 18 h. The reaction solution was cooled to –60 °C, and m-CPBA  (0.78 g, 
57–86%) was added. The mixture was stirred at this temperature for 60 min and slowly 
warmed to rt, after removal of the cooling bath. The solution was diluted to 60 mL with 
dichloromethane, washed with saturated aqueous sodium hydrogen carbonate (2 × 30 
mL), and the aqueous phase was extracted with dichloromethane (60 mL). The 
combined organic phases were dried with magnesium sulfate, filtered, and 
concentrated. The residue was purified by chromatography on silica gel 
(hexanes/acetone, 3:1) to afford product 2.18 (0.238 g, 99%) as a syrup.  
[α] D296 K = –14.7 (c = 5.6, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 7.32– 7.17 (m, 50 H), 
5.13–4.81 (m, 21 H), 4.76–4.52 (m, 5 H), 4.45–4.17 (m, 4 H), 3.94–3.82 (m, 2 H), 3.09–
3.03 (m, 2 H), 1.46–1.18 (m, 8 H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 155.9, 137.6, 
137.3, 136.3, 135.6, 135.6, 135.5, 135.3, 135.2, 135.2, 135.1, 128.0, 128.0, 127.9, 
























































74.7, 74.3, 74.1, 74.0, 70.0, 69.9, 69.6, 69.3, 69.1, 69.0, 68.9, 68.9, 68.8, 67.7, 67.6, 
67.5, 67.4, 66.0, 52.9, 40.4, 29.5, 29.4, 29.1, 25.5, 24.4 ppm. 31P NMR (121.5 MHz, 
CDCl3): δ = 0.13, –0.03, –0.21, –0.56 ppm. MALDI-HRMS: calcd. For C85H93NO22P4Na 
[M + Na]+ 1626.5032; found 1626.5042. 
 
1D-1-(6-Aminohexyl sodium phosphate)-myo-inositol 3,4,5-Tris(disodium 
phosphate) (2.1):  
 
Palladium hydroxide (20%) on charcoal (0.30 g) was added to a solution of a compound 
2.18 (0.23 g, 0.143 mmol) in methanol (15–40 mL). The mixture was then stirred at rt 
with 1 atm of hydrogen (balloon) for 3 days. The catalyst was removed by filtration and 
the residue washed with methanol. The solvent was removed in vacuo, and the crude 
product was dissolved in water and stirred with Chelex 100 resin (Sigma, Na+ form) for 3 
h. The resin was removed by filtration and the filtrate lyophilized to give the 
corresponding amino conjugate 2.1 (88 mg, 100%) as a white solid.  
[α] D296 K = –7.2 (c = 0.68, H2O). 1H NMR (400 MHz, D2O): δ = 4.04 (br. s, 2 H), 4.22–
3.95 (m, 6 H), 3.02 (br. s, 2 H), 1.68 (br. s, 4 H), 1.44 (br. s, 4 H) ppm. 13C NMR (100.6 









































ppm. 31P NMR (121.5 MHz, D2O): δ = 2.75, 2.54, 1.78, 0.89 ppm. MALDI-HRMS: calcd. 
for C12H31NO18P4Na [M + Na]+ 624.0389; found 624.0301. 
 
2.8.3 Assay Procedure 
Microarray Assay with Akt-PH: 
The wash buffer employed for all glass slide experiments was 20 mM Tris buffer at pH 
7.74, with 0.05% tween and all washings were done in petri dishes with agitation. For 
the uniform concentration grids, 12 solutions of 2.19 at 500 µM were printed onto the 
slide in 20 replicates (2 grids of 12x10) and then incubated in a humidifying chamber 
overnight. For the varying concentration grids, 12 solutions of 2.19 at 0, 15, 30, 45, 60, 
75, 100, 200, 250, 300, 400, and 500 µM were printed onto the slide in 20 replicates (2 
grids of 12x10) and incubated in a humidifying chamber overnight. The grids were 
outlined with a marker, and the slide was washed 3x with wash buffer. It was then dried 
under a stream of nitrogen, 50 µg/mL Akt-GST in wash buffer was added, and 
incubated for 1 h in a humidifying chamber. The slide was washed 3x with wash buffer, 
dried under a stream of nitrogen, and a solution of 0.2 µg/mL rabbit anti-GST and 0.1 
µg/mL goat anti-rabbit–Cy3 in wash buffer was added and incubated in a humidifying 
chamber for 1 h. Following the incubation, the slide was washed 2x with wash buffer, 3x 
with deionized water, dried under a stream of nitrogen and then scanned for 





Microarray Assay for Profilin: 
The wash buffer employed for all glass slide experiments was 20 mM Tris buffer at pH 
7.74, with 0.05% tween and all washings were done in petri dishes with agitation. 
Twelve solutions of 2.20 at 0, 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, and 400 µM 
were printed onto the slide in 20 replicates (2 grids of 12x10) and incubated in a 
humidifying chamber overnight. The grids were outlined with a marker, and the slide 
was washed 2x with wash buffer. It was then dried under a stream of nitrogen. From left 
to right in sets of 4 grids, 0.05 µg/mL, 0.5 µg/mL, 5 µg/mL, and 50 µg/mL profilin in wash 
buffer was added, and incubated for 1 h in a humidifying chamber. The slide was 
washed 2x with wash buffer, dried under a stream of nitrogen, and a solution of 0.2 
µg/mL rabbit anti-profilin and 0.1 µg/mL goat anti-rabbit–Cy3 in wash buffer was added 
and incubated in a humidifying chamber for 1.5 h. Following the incubation, the slide 
was washed 3x with deionized water, dried under a stream of nitrogen and then 
scanned for fluorescence detecting at 532 nm. 
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Chapter 3: Exploiting Copper-Free Click Chemistry for Membrane 
Derivatization 
3.1 Background and Significance 
Functionalizing the surface of intact membrane bilayers has been a topic of 
recent interest because of the wide range of applications that can be achieved by 
exploiting membranes, including their use as pharmaceutical carriers with gene delivery 
and cancer therapy as the main attractors to this field.225-227 These systems typically 
involve the use of varying targeting groups for in vivo delivery, and liposomes are 
effective for these applications because they are biologically inert and are intrinsic 
containers for a variety of cargo.69-71,227 The choice of targeting groups to use is an 
important one because of the complex environments in which these membranes exist. 
Proper execution of controlled membrane derivatization should ideally combine several 
features. For example, the reactive group that allows functionalization must be 
presented on the surface of the membrane, so it must be stable and compatible with the 
exterior aqueous environment, and the conjugations should occur under mild reaction 
conditions and result in high yields and chemoselectivity.  
As mentioned in Chapter 1, in recent years, copper catalyzed azide–alkyne 
cycloaddition (CuAAC), also known as click chemistry, has become an invaluable tool 
for a litany of applications.86-89 Although there have been numerous reports of click 
chemistry in biological systems, the first example of click chemistry in liposomes was 
reported in 2006 by Schuber and co-workers.228 They reported derivatizing the surface 
of alkynyl-containing liposomes with azido-mannose moieties by the use of copper-
 
 89 
catalyzed click chemistry. In this report, they first performed a model reaction using 
simplified click partners, a tetraethyleneglycol (TEG) azide and 5-hexynoic acid. They 
hoped that the reaction conditions used in this model system would be capable of being 
extended to the liposome surface derivatization reaction, but this was not the case. 
When the same model reaction conditions were used for the liposome click reaction, 
they saw no appreciable yield of conjugated liposomes, but instead, they observed 
liposome decomposition. In the end, they remedied this by the addition of a copper(I) 
stabilizing ligand, bathophenanthrolinedisulfonate, which led to much improved 
conjugation yields. In a final study, they evaluated the turbidity increase (agglutination) 
of the liposome suspensions upon the addition of concanavalin A resulting from 
clustering and multivalent binding of the mannosylated liposomes to con A, providing 
evidence that the mannose moieties are exposed and available for binding.  
In the same year, Kros and co-workers also reported the use of copper-catalyzed 
click chemistry on the surface of liposomes and the reaction was monitored by a FRET 
assay.229 In this study, a fluorescent azido-tagged peptide was synthesized by solid 
phase peptide synthesis that was subsequently conjugated to the surface of liposomes 
through the use of copper(I) bromide. The azido-peptide contained a fluorescent NBD, 
and the liposomes contained a fluorescent, commercially available rhodamine-PE. 
These two fluorophores were used to monitor the reaction by FRET, whereby upon click 
conjugation to the liposome surface, the FRET signal is activated because of the near 
proximity of the fluorophores. This reaction was even visible to the naked eye and could 
be monitored by a colorimetric assay after dialyzing away any of the unreacted dye. 
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While this report only uses the FRET assay and azido-NBD peptide, the assay could be 
extended to append other azido-peptides to liposome surfaces for targeting 
purposes.230 
In a later report, Sun and co-workers have used the Staudinger ligation to attach 
azido-lactose moieties to membrane surfaces containing a phosphine conjugated PE.83 
They reported that the integrity of the liposomes was unaffected after being exposed to 
their reaction conditions as monitored by dynamic light scattering (DLS), and the 
leakiness was evaluated by encapsulation of a self-quenching concentration of 5(6)-
carboxyfluorescein (CBF) and fluorescence monitoring. An agglutination assay was 
performed by the addition of Arachis hypogea, which showed an accumulation of large 
particles, as determined by DLS, providing evidence that the lactose residues were 
conjugated to the liposome surfaces and were available to bind the protein multivalently. 
Finally, the stability of the liposomes was assessed through particle size observation 
over a period of fifteen days, and the sugar-conjugated liposomes proved to be stable 
for longer periods than the unreacted liposomes, supporting that sugar moieties such as 
GM1 affect the ability for liposomes to aggregate and therefore prolong their lifetimes.231  
Following these initial reports, Boxer and co-workers have used copper-catalyzed 
click chemistry to study DNA-mediated membrane docking.232 Building off of a previous 
report, they successfully observed vesicle collision and docking onto a fluid-supported 
bilayer as mediated by complimentary DNA strands bearing click partners to prevent 
reversibility.233 The DNA strands on the vesicles are modified with an alkyne while the 
fluid-supported bilayer contains an azido-PE. In the reaction, the complimentary strands 
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presented on the vesicle and fluid-supported bilayer easily interact in solution and 
zipper together. This tethers the vesicle to the fluid-supported bilayer surface, and upon 
the addition of copper(I) catalyst, the click reaction takes place between the fluid-
supported bilayer and the vesicle, covalently linking them together. When the salt 
concentration is lowered, the DNA uncoils, but the vesicle remains docked on the 
surface because of this covalent triazole linkage.  
 CuAAC has also been used by Cai and co-workers for the attachment of RGD-
peptides and AMP-peptides to polymerized liposomes that were then used for in vivo 
delivery.234,235 In their initial findings, they used polymerized liposomes (made by UV 
irradiation of lipids containing diacetylene tails) displaying alkyne moieties from an 
alkynyl-TEG-diacetylene lipid and then clicked on a fluorogenic coumarin to optimize the 
click conditions.234 Next, they clicked on a GRGD peptide, which targets integrin 
receptors on cell membranes, and carboxyfluorescein to visualize the liposomes that 
are targeted to the cells. An important note is that those liposomes were used for in vivo 
delivery, but the click reaction was not performed in vivo but prior to the delivery. In an 
additional report, Cai et al. have formulated polymerized liposomes composed of 10,12-
pentacosadiynoic acid that they then coupled to propargylamine, resulting in 
polymerized liposomes displaying terminal alkynes on their surfaces.235 These 
liposomes underwent a click reaction to append an antimicrobial peptide, IG-25, to the 
surface and were then tested for effectiveness against Pseudomonas aeruginosa, the 
most common culprit of contact lens related eye infection.  
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Zumbuehl and co-workers have recently reported the use of copper-catalyzed 
click chemistry to fuse vesicles.236 Ether tailed lipids are synthesized containing an 
azide and a terminal alkyne that are then incorporated into liposomes. They discovered 
that upon the addition of these click partner-containing liposomes, when formulated with 
PC, no vesicle aggregates formed, but when a positively charged lipid was incorporated 
into the alkyne-containing liposomes, they formed aggregates and spontaneously fused. 
While copper-catalyzed click chemistry has been used in a handful of reports 
functionalizing the surface of liposomes, this research has also uncovered some 
problems associated with CuAAC in membrane systems. For example, initial attempts 
at functionalization using standard copper-catalyzed click chemistry led to liposome 
decomposition and very low conjugation yields.228 Even the use of polymerized 
liposomes, which are formed via cross-linking of the lipid tails and are inherently more 
stable than their non-polymerized counterparts, led to membrane decomposition.234 The 
use of polymerized liposomes is also at a disadvantage to normal liposomes as the 
polymerization and cross-linking of the lipid tails restricts the fluidity and fusion that are 
beneficial for applications. Because of the expansive applications of click chemistry, it 
has become imperative to circumvent these problems that impede click chemistry from 
being applicable in vivo. There have been efforts for ligand-based methods of chelating 
the requisite copper catalyst to circumvent the aforementioned problems, but these 
approaches are also hampered by the need to deliver the copper and ligands to the 
reactive site, and even still, cytotoxicity exists.107 Because of the copper catalyst 
cytotoxicity and our desire to eventually move into in vivo labeling and delivery, we 
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chose to exploit copper-free click chemistry for use as a targeting moiety in a liposome-
based delivery system.  
Among the reported cyclooctynes, the aza-dibenzocyclooctynes (ADIBOs) boast 
fast kinetics, synthetic ease, and have proven to be quite robust.88,116,237-239 After some 
unsuccessful attempts with Bertozzi’s initial cyclooctyne moiety 1.1, we found the 
recently published report by Popik and co-workers, where they reported surface 
functionalization onto modified glass slides via copper-free click chemistry.238 In this 
report, they accomplished clicking onto a glass surface modified with either an azide or 
aza-dibenzocyclooctyne (ADIBO), which was then detected via a fluorescent avidin 
binding to the appended biotin moiety. Since we desire to use click-driven membrane 
reactions, this seemed the perfect system to extend to our membrane systems. 
With the goal of copper-free click driven vesicle fusion in mind, we set out to 
prove that we could exploit copper-free click chemistry to derivatize the surfaces of 
intact liposomes. We chose an immobilization-based strategy for validating surface 
derivatization as a high-throughput method that we have previously had success with.129 
In our previous assay, we were able to anchor whole, intact liposomes onto a 
streptavidin surface through the use of a synthetic biotinylated lipid incorporated into the 
liposomes. The use of a fluorescent lipid in those liposomes resulted in a fluorescent 
signal that increased with increasing amounts of immobilized liposomes. In this study, in 
order to prove that the liposomes remained intact after surface deposition we performed 
the immobilization assay using dye-loaded liposomes. In the dye-encapsulated 
liposomes, the fluorophore inside the liposome is self-quenched, but upon detergent 
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addition, the fluorophore is released resulting in a dramatic fluorescence increase. This 
provides evidence that the liposomes remain intact when deposited and immobilized on 
the streptavidin-coated microplate surface, since the use of detergent is required to 
rupture the liposomes.  
3.2 Results and Discussion 
Since we knew that intact liposomes could be immobilized on streptavidin-coated 
microplate surfaces, we approached a copper-free click-driven immobilization in a 
similar fashion. To achieve this, we designed an experiment where we could make 
liposomes that contained an azido-lipid and a fluorophore, in addition to the normal 
phosphatidylcholine (PC) as the structural backbone of the membrane.240 Figure 3.1 
outlines the copper-free click-driven immobilization assay performed, in which a 
cycloooctyne that is tethered to a biotin is placed in a streptavidin-coated 96-well plate 
and then the fluorescent, azido-tagged liposomes are added and incubated. The 
liposomes that have achieved a successful click reaction will display a biotin on their 
surface, and because of the well-known high affinity interaction of biotin and avidin, the 
entire liposome will be immobilized, resulting in fluorescence observed on the 
microplate surface. After several washings to remove unbound liposomes, the 





Figure 3.1. Cartoon depiction of the assay performed. Fluorescent azido-liposomes (containing 
fluorescent NBD-PE, azido-lipid 3.12, and PC) were incubated with ADIBO-biotin in a streptavidin-
coated 96-well microplate for 4 hours, wells were washed and fluorescence was measured. 
To make the azido-tagged lipid 3.12, we began with a modular lipid 3.18 that has 
afforded us previous success.129 This lipid is beneficial because it can be used to easily 
derive a number of compounds through the use of click chemistry with any alkyne. The 
resulting triazole in the product provides the needed polarity to keep the lipid headgroup 
properly oriented toward the aqueous exterior and is easily purified. The use of a natural 
phospholipid, such as PE, could be used as a synthetic precursor but yields much more 
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The synthesis of azido lipid scaffold 3.18 begins by tosylating S-glyceroacetonide 
followed by azide displacement to give 3.16. The acetonide is then removed under 
acidic conditions and coupled to stearic acid with the use of coupling reagents to give 
the azido-lipid scaffold 3.18. Our group has used this lipid scaffold in the 
aforementioned liposome immobilization assay for synthesizing the biotinylated lipid as 
well as the fluorescent lipid that is incorporated in those liposomes.129 
  
Figure 3.2. Synthesis of the azido-lipid 3.18 used as a common scaffold for various lipid analogs. 
The azido-tagged lipid 3.12 was initially synthesized by Matt Smith in our group, 
as outlined in Figure 3.3, beginning with the reaction of tetraethylene glycol with 
ethyldiazoacetate in the presence of copper (II) triflate to afford the previously reported 
tetraethylene glycol (TEG) ethyl ester 3.19.129 The ester was then deprotected using 
sodium hydroxide and coupled to propargylamine with the use of coupling reagents to 
provide the TEG-alkyne 3.20. A click reaction was performed using the alkyne 3.20 and 
the azide–lipid 3.18129 to give the lipid alcohol 3.21. The alcohol of 3.21 was then 
converted to a mesylate and finally displaced by azide to give the azido-tagged lipid 






























Figure 3.3. Synthesis of azido-lipid 3.12 for incorporation into liposomes. 
In addition to this azido-lipid 3.12, we needed to include a fluorescent lipid. In our 
previous liposome assay, we used a synthetic 7-nitrobenzo-2-oxa-1,3-diazole (NBD) 
lipid to make the liposomes fluorescent. In this assay, we chose to use the same 
fluorophore but in a commercially available format, a phosphatidylethanolamine 
derivative, NBD-PE.  
The liposomes were prepared by measuring out an amount of each dried lipid 
(azido-lipid 3.12, NBD-PE, and PC) and dissolving them in chloroform to provide 
individual stock solutions. These chloroform solutions were then used to measure out a 
known volume of each lipid into a glass vial to give the proper ratios (1% azido-lipid 
3.12, 1% NBD-PE, and 98% PC) of each lipid in the final liposome concentration. The 
chloroform was evaporated under a stream of nitrogen, and the dried lipid film was 

































































of 500 µL of buffer and rotating on a rotary evaporator for 40 minutes at 40 °C. 
Following this hydration, the liposomes were subjected to 10 freeze-thaw cycles in a dry 
ice/acetone bath and 40 °C water bath. The resulting liposome suspension was 
extruded through a 200 nm polycarbonate membrane to provide uniform sized, 
unilamilar liposomes as evidenced by DLS. Initally, we attempted to synthesize multiple 
cyclooctyne compounds, but after limited success, we settled on the ADIBO-biotin 3.13 
compound that was generously donated by Popik and co-workers.238 The assay begins 
with diluting a stock solution of the ADIBO-biotin 3.13 in buffer to twelve concentrations 
(0, 0.05, 0.15, 0.30, 0.45, 0.60, 0.75, 1.0, 1.25, 1.50, 1.75, and 2.0 µM). After washing 
the streptavidin-coated microplate with buffer, the twelve solutions of ADIBO-biotin 3.13 
were placed in the wells, immediately followed by 250 µM liposomes, which provides 
final ADIBO-biotin concentrations of 0, 0.025, 0.075, 0.15, 0.225, 0.3, 0.375, 0.5, 0.625, 
0.75, 0.875, and 1.0 µM and 125 µM total liposomes, containing 1.25 µM azido-lipid 
3.12 and 1.25 µM NBD-PE. The concentration of liposomes was held constant across 
the varied concentration of the ADIBO-biotin so that any fluorescence that was detected 
was from the clicked product, not residual liposomes.  
The fluorescence results of the immobilization and several controls are shown in 
Figure 3.4. There is a dose-dependent response (blue diamond) showing the 
fluorescence results obtained from incubating the fluorescent, azido-tagged liposomes 
with the ADIBO-biotin 3.13. The results show that the increase of cyclooctyne correlated 
to an increase in fluorescence, resulting from a greater amount of immobilized 
liposomes, and therefore more of the click product. To conclude that the increased 
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fluorescence is directly a result of the click reaction and immobilization of the liposomes, 
we performed several control reactions. Firstly, we incubated the fluorescent, azido-
tagged liposomes with an acyclic alkyne–biotin 3.23, which should not yield reaction in 
the absence of copper, as was observed (red square). Secondly, we incubated 
fluorescent liposomes that did not contain the azido-lipid 3.12, which also abrogated the 
fluorescence signal (green triangle). These two controls show the lack of appreciable 
fluorescence signal, allowing us to conclude that the click reaction is taking place on the 





Figure 3.4. Results from liposome derivatization and immobilization studies and control 
experiments. 
The last remaining control reaction was undertaken by repeating the same 
process with the ADIBO–biotin 3.13 and fluorescent azido-tagged liposomes, only this 
time the microplate was first incubated with biotin alone. This step blocked the surface 
of the microplate with natural biotin, which has a documented higher affinity for avidin 
than amide-linked biotin and therefore would not be displaced upon addition of the 















































Figure 3.5. Acyclic alkyne-biotin used in a control reaction. 
Previous to this successful liposome surface derivatization, we tried various 
avenues that did not yield success. We initially tried to synthesize a cyclooctyne-lipid to 
be incorporated into liposomes that could then be labeled via various azide-containing 
reagents. This strategy was desired since the previously discussed azido-sugars and 
their exclusive incorporation into cancer cells already prove the bioorthogonality that we 
wished to exploit as our targeting moiety.74 Our initial attempt was using a different 
cyclooctyne, based off of the original cyclooctyne reported by Bertozzi and co-
workers,108 in which we synthesized compound 1.1. This synthetic octyne was then 
appended to the end of a lipid molecule as outlined in Figure 3.7. Using this octyne-lipid 
3.32, we attempted FRET-based assays. The assay works as depicted in Figure 3.8, 
whereby the liposome is loaded with one of the FRET pairs, a donor or acceptor lipid, 
cyclooctyne-lipid 3.32, and PC. The remaining FRET partner is tethered to an azide and 
the click reaction is attempted. These assays were carried out on the fluorimeter 




















Figure 3.6. Synthesis of Bertozzi's octyne 1.1.108 
 












































































































Figure 3.8. Cartoon depiction of the FRET-based approach using octynyl liposomes and an azido-
fluorophore. 
Our initial attempts with this FRET-based approach used rhodamine–azide 3.33, 
which contains a six carbon linker between the dye and azide. This assay never yielded 
dependable results. The fluorescence signal often looked the same regardless of 
whether the cyclooctyne-lipid 3.32 was included, which could have been caused by the 
six-carbon chain on the rhodamine–azide burying into the membrane. This rhodamine–
azide also suffered from poor water solubility. Attempts to overcome this included 
differing buffers with varying pH ranges, heating and sonication. The addition of 
dimethylsulfoxide (DMSO) solubilized the rhodamine–azide but still failed to produce 
desirable results.  Because of these fluorophore downfalls, we investigated other routes. 
Based on the report by Kros and co-workers where they employed an amino acid based 
fluorophore–azide for clicking onto liposome surfaces followed by FRET detection,229 
we synthesized a peptide version of an NBD-azide and attempted our assay. Since they 
used the FRET-donor (NBD) with the azide, the FRET-acceptor (rhodamine) must be 
included as a lipid in the liposome. This attempt also did not lead to success under our 




































been using is susceptible to decomposing, even after being stored at -20 ºC.111 Upon 
this discovery, we investigated other cyclooctyne moieties and since aza-
dibenzocyclooctynes had been reported at that time, to benefit from their reported 
synthetic ease, stability, and fast kinetics, we chose them. Having seen the previously 
mentioned paper by Popik and co-workers, we acquired some of the aza-
dibenzocyclooctyne as a succinimidyl ester to get our assays started. Attempts at 
putting this onto phosphatidylethanolamine (PE) or a triazole-based lipid were not 
successful, and our FRET-based approach hinged on the cyclooctyne being part of the 
membrane. A potential problem in this ADIBO-based cyclooctyne being incorporated 
into membranes is the hydrophobicity of the cycloooctyne moiety. It is possible that this 
cyclooctyne is not presented properly on the membrane surface, facing the aqueous 
exterior, but instead may be buried in the hydrophobic membrane core, complicating the 
click derivatization. To eventually use this system for in vivo delivery by membrane 
labeling and fusion, it will be necessary to create a cyclooctyne lipid that can be 
incorportated in the liposomes for use as a targeting moiety. 
 













Figure 3.10. Original ADIBO succinimidyl ester 3.35 and steps for preparing ADIBO lipid via 








































































3.3 Modification of glass slides  
In addition to the previously discussed microplate assay, we have attempted to 
miniaturize this assay to be performed on avidin-modified glass slides in true microarray 
format. We have previously reported the use of immobilized whole liposomes to study 
DAG binding of protein kinase C, and we would like to exploit this system of studying 
protein–binding in a native membrane environment to be achieved through microarray 
analysis.129 While in the previously discussed assay we used NBD-PE as our 
fluorescent lipid, based on the wavelength detection limits of the slide scanner, it only 
recognizes fluorophores that emit at 533 or 650 nm. Thus, the fluorophore used in these 
studies is commercially available rhodamine-PE.  
We initially attempted to simplify the system by printing intact liposomes. An 
attempt at this assay is shown in Figure 3.11. The image shown here contains different 
reactions in each column. The first and second columns were obtained by printing 
diluted stock solutions of the reaction of alkynyl-liposomes with azido-biotin and octynyl-
liposomes with azido-biotin. In the third and fourth columns, the roles are reversed and 
azido-liposomes are incubated with alkynyl-biotin and octynyl-biotin, respectively. The 
fifth column is a control reaction where liposomes containing an already biotinylated 
lipid were printed. Columns six and seven contain control reactions with only liposomes 
(azido and octynyl) being printed, which, as seen, still yields a fluorescent signal. These 
last two columns provide evidence that the liposomes may not remain intact when 
printed on the surface, but instead are being ruptured. It seems that the mechanical 
impact of the robot pin may be the cause of these ruptured liposomes, which is not 
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surprising considering that liposomes are quite fragile. There is also a possibility that the 
washing procedure performed on this slide is insufficient. Recently, Sun and co-workers 
reported the printing of intact liposomes and use of control studies that seem to indicate 
that their liposomes are not ruptured upon contact from pin printing.241 Their washing 
procedure is much more intensive than the one that has been used here in that they 
wash for a total of 6 hours, while we have only washed for 1–2 hours. Because of the 
directly printed fluorophore, it requires extensive washing to remove any unbound 
species, so this printing of the intact liposomes should be reinvestigated with more 
rigorous washing procedures.  
 
Figure 3.11. Fluorescent image of printed liposomes containing biotinylated tags. 
Upon the initial observed failure of the printing of intact liposomes, we chose to 
instead print the click ligands, and then incubate with liposomes containing the 
appropriate click partner, as outlined in Figure 3.12. So far, we have seen fluorescence 
on the slide that appears to be a result of a clicked product as seen in Figure 3.13 and 
Figure 3.15. In Figure 3.13, the ADIBO-biotin 3.13 has been printed and the slide 
incubated with fluorescent, azido-lipid 3.12-containing liposomes in increasing 
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concentrations from left to right for each set of four grids, 125 µM, 250 µM, 500 µM, and 
1 mM liposomes containing 1.25, 2.5, 5, and 10 µM azido-lipid 3.12. The plot of the 
fluorescence of the first (top, leftmost) grid is shown in Figure 3.14. This plot shows a 
general dose-dependent response, as expected. Plots of the other grids display a 
similar curve and have been excluded for clarity. Following this, a control similar to the 
previous assay was undertaken. Figure 3.15 shows the results of the assay performed 
where the ADIBO-biotin 3.13 was printed along with the same acycylic alkyne 3.23 from 
the previous assay. In this case, the background is very high, but the grids remain 
visible. The plot of the fluorescence of these grids yields a dose-dependent response for 
the acyclic alkyne 3.23 but the plot for the ADIBO-biotin 3.13 is not as desired, it is very 
flat. This may not necessarily mean the assay is futile, as fluorescence quenching may 
cause the problem here, which may mean the ADIBO-biotin reaction is performing as 
expected, but the concentration of liposomes and fluorophore in any region is too high. 
This can be remedied by incubating with a much lower concentration of liposomes and 
printing the alkyne reagents at even lower concentrations. Because of inconsistencies in 




Figure 3.12. Cartoon depiction of the immobilization of liposomes by copper-free click chemistry 
using microarray. 
 
Figure 3.13. Fluorescent image of the liposome assay that has been incubated with increasing 






















Figure 3.14. Plot of fluorescence intensity of the top leftmost grid from Figure 3.13. 
 
Figure 3.15. Fluorescent image of the liposome microarray assay with ADIBO-biotin 3.13 (columns 
2, 4, 6 and 8) and alkyne biotin 3.23 (columns 1, 3, 5, and 7) printed from 0–5 nM and then 































Concentration of ADIBO-biotin printed (nM) 




3.4.1 General Considerations 
Reagents were generally purchased from Acros, Aldrich or AK Scientific and used as 
received. Dry solvents were obtained from a Pure Solv solvent delivery system 
purchased from Innovative Technology, Inc. Column chromatography was performed 
using 230−400 mesh silica gel purchased from Sorbent Technologies and C18 (17%) 
reverse phase SPE columns (6 mL, 2g) purchased from Silicycle. NMR spectra were 
obtained using a Varian Mercury 300 spectrometer, a Bruker Avance 400 spectrometer, 
and a Varian 500 spectrometer. Mass spectra were obtained with JEOL DART-
AccuTOF spectrometer and ABI Voyager DE Pro MALDI spectrometer with high 
resolution capabilities. Optical rotation values were obtained using a Perkin-Elmer 241 
polarimeter. L-α-phosphatidylcholine (PC) and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD-PE) 
were obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). Liposome extruder and 
polycarbonate membranes were obtained from Avestin (Ottawa, Canada). Microplate-
based fluorescence measurements were performed using a BioTek Synergy 2 multi-
detection microplate reader. Black reacti-bind streptavidin high binding capacity (HBC) 
coated 96-well microplates were purchased from Pierce Biotechnology (Rockford, IL). 
SuperAvidin slides were purchased from Arrayit Corporation (Sunnyvale, CA). Slide 
printing was performed using a BioRad VersArray ChipWriter Pro robotic pin printer 




3.4.2 Synthetic Procedures 
(S)-3-(4-(16-Hydroxy-3-oxo-5,8-11,14-tetraoxa-2-azahexadecyl)-1H-1,2,3-triazol-1-
yl)propane-1,2-diyl distearate (3.21):  
 
Alkyne-alcohol 3.20 (69 mg, 0.238 mmol) and (S)-3-azidopropane-1,2-diyl distearate 
(3.18, 155 mg, 0.238 mmol) were dissolved in tetrahydrofuran (1.5 mL). Copper sulfate 
pentahydrate (173 mg, 0.693 mmol) and sodium ascorbate (275 mg, 1.386 mmol) were 
then added, along with water (0.5 mL). The reaction was stirred at rt overnight, and the 
solvent was then removed under reduced pressure. Column chromatography with silica 
gel and a solvent system of 10% methanol-chloroform afforded 3.21 as a white solid 
(131 mg, 59%).  
[α]D296 K = +1.22 (c = 5.25, CHCl3). 1H NMR (300 MHz, CDCl3) δ = 7.97 (t, J = 5.6 Hz, 
1H), 7.65 (s, 1H), 5.39–5.36 (m, 1H), 4.64–4.54 (m, 4H), 4.32 (dd, J = 4.1, 12 Hz, 1H), 
4.08–4.01 (m, 3H), 3.73–3.43 (m, 17H), 2.36–2.27 (m, 4H), 1.62–1.57 (m, 4H), 1.26 (b 
s, 56H), 0.88 (t, J = 6.3 Hz, 6H) ppm. 13C NMR (75.5 MHz, CDCl3) δ = 173.1, 172.6, 
145.3, 123.6, 72.6, 70.9, 70.5, 70.4, 70.22, 70.18, 69.3, 62.0, 61.5, 50.0, 34.2, 34.0, 
31.9, 29.72, 29.67, 29.5, 29.4, 29.3, 29.1, 29.0, 24.8, 24.7, 22.7, 14.1 ppm. MALDI–



































yl)propane-1,2-diyl distearate (3.12):  
 
Lipid alcohol 3.21 (129 mg, 0.137 mmol) was dissolved in tetrahydrofuran (3 mL) and 
cooled to 0 ºC under nitrogen. With stirring, triethylamine (57 µL, 0.411 mmol) and 
methanesulfonyl chloride (10.8 µL, 0.138 mmol) were added. Stirring was continued at 0 
ºC for 1 h. The solvent was removed under reduced pressure and the residue was 
dissolved in N,N-dimethylformamide. Sodium azide (17.8 mg, 0.274 mmol) was added 
and the reaction was heated at 85 ºC overnight. The solvent was next removed under 
reduced pressure and column chromatography with silica gel and a solvent system of 
5% methanol-chloroform afforded 3.12 as a tan solid (103 mg, 78%).  
[α]D296 K = –0.17 (c = 4.12, CHCl3). 1H NMR (300 MHz, CDCl3) δ = 7.72 (b s, 1H), 7.62 
(s, 1H), 5.39–5.35 (m, 1H), 4.62–4.50 (m, 4H), 4.31 (dd, J = 4.2, 12 Hz, 1H), 4.08–4.00 
(m, 3H), 3.77–3.61 (m, 14H), 3.39 (t, J = 4.8 Hz, 2H), 2.36–2.27 (m, 4H), 1.62–1.57 (m, 
4H), 1.25 (b s, 56H), 0.88 (t, J = 6.3 Hz, 6H) ppm. 13C NMR (75.5 MHz, CDCl3) δ = 
173.1, 172.5, 145.2, 123.4, 71.3, 71.1, 70.7, 70.6, 70.4, 70.2, 70.0, 69.3, 62.0, 50.6, 
50.0, 42.8, 34.2, 34.0, 31.9, 29.72, 29.68, 29.6, 29.5, 29.4, 29.3, 29.1, 29.0, 24.8, 24.7, 






























yl)propane-1,2-diyl dipropionate (3.31):  
 
Alkyne 3.30 (164 mg, 0.422 mmol) and (S)-3-azidopropane-1,2-diyl distearate 3.18 (329 
mg, 0.507 mmol) were dissolved in THF (2.5 mL). Copper sulfate pentahydrate (127 
mg, 0.507 mmol) and sodium ascorbate (201 mg, 1.02 mmol) were added along with 
water (0.5 mL). The reaction was stirred at rt overnight and the solvent was removed 
under reduced pressure. Column chromatography with silica gel and a solvent system 
of 50% acetone-chloroform afforded 3.31 as a white solid (272 mg, 62%). 
[α]D296 K = + 0.21 (C = 4.24, CHCl3). 1H NMR (300 MHz, CDCl3 + CD3OD) δ = 7.91 (bs, 
1H), 7.70 (bs, 1H), 5.40–5.36 (m, 2H), 4.61–4.55 (m, 4H), 4.33 (dd, J = 4.1, 12.2 Hz, 
1H), 4.09–4.01 (m, 3H), 3.66–3.52 (m, 14H), 3.31–3.29 (m, 2H), 2.37–2.28 (m, 4H), 
1.64–1.55 (m, 4H), 1.44 (s, 9H), 1.26 (bs, 56H), 0.88 (t, J = 6.6 Hz, 6H) ppm. 13C NMR 
(100.6 MHz, CDCl3 + CD3OD) δ = 173.1, 172.5, 170.2, 156.0, 145.4, 123.6, 79.1, 71.1, 
70.5, 70.3, 69.4, 69.3, 62.0, 50.1, 40.3, 34.0, 31.93, 31.88, 29.7, 28.4, 24.8, 22.7, 14.1 



































methyl)-1H-1,2,3-triazol-1-yl)propane-1,2-diyl dipropionate (3.32): 
 
The Boc protected amine 3.31 (35 mg, 0.034 mmol) was dissolved in dichloromethane 
(1 mL) and trifluoroacetic acid (1 mL) was added. The reaction was stirred at rt for 2 h. 
The solvent was removed and the product placed under high vacuum for 2 h. The 
amine was then dissolved in dichloromethane (1 mL) and N-methylmorpholine (26 µL, 
0.232 mmol) was added. Separately, the octyne acid 1.1 (6 mg, 0.023 mmol), 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (9 mg, 0.047 mmol), and 4-dimethylaminopyridine 
(4.3 mg, 0.035 mmol) were dissolved in CH2Cl2 (1 mL) and then added to the amine 
mixture. The reaction was stirred at rt overnight and the solvent removed under reduced 
pressure. Column chromatography with silica gel and a solvent system of 0-10% 
methanol-dichloromethane gave 3.32 as a white solid (31 mg, 77%).  
1H NMR (300 MHz, CDCl3) δ = 7.80 (d, J = 6 Hz, 2H), 7.71 (bs, 1H), 7.59 (s, 1H), 7.39 
(d, J = 6 Hz, 2H), 7.06 (bs, 1H), 5.36–5.30 (m, 2H), 4.73–4.69 (m, 1H), 4.55–4.53 (m, 
4H), 4.46–4.41 (m, 1H), 4.31–4.22 (m, 2H), 4.07–3.98 (m, 3H), 3.66–3.63 (m, 14H), 
2.31 (quint, J = 6 Hz, 4H), 2.21–2.07 (m, 2H), 2.05–1.93 (m, 2H), 1.85 (bs, 3H), 1.67–
1.55 (m, 6H), 1.27–1.24 (m, 56H), 0.88–0.86 (m, 6H) ppm. MALDI–HRMS [M + Na]+ 








































3.4.3 Assay Procedures 
Fluorescent Azido-Labeled Liposome Preparation  
Stock solutions were made of synthetic azido-lipid 3.12, NBD-PE, and PC. Examples of 
each stock solution used are as follows: 1.5 mg azido-lipid 3.12, 1.0 mg NBD-PE, and 
50 mg PC were each weighed into separate vials and dissolved in 1 mL chloroform to 
form stock solutions of 1.56 mM azido-lipid 3.12, 1.08 mM NBD-PE, and 65.8 mM PC. 
Using these stock solutions, 12.8 µL azido-lipid 3.12 stock (1%), 18.5 µL NBD-PE stock 
(1%), and 29.8 µL PC stock (98%) were combined in a glass vial. In addition, liposomes 
lacking azido-lipid 3.12 were prepared by combining 9.3 µL NBD-PE (1%) and 15.0 µL 
PC (99%). In both, the chloroform was removed under a stream of nitrogen and placed  
under vacuum for 1 h. The dried lipids were then hydrated by adding 500 µL of 0.5X 
PBS buffer, pH 7.4, and rotated on a rotary evaporator for 40 min at 40 ºC. The 
liposomes were then subjected to 10 freeze-thaw cycles and extruded (19 times) to 
uniform size and lamellarity using a 200 nm polycarbonate filter. The resulting solutions 
were then diluted to a total volume of 4 mL, which yielded a concentration of 500 µM 
total liposome suspension.  
 
Membrane Derivatization and Immobilization via Copper-Free Click Chemistry  
Stock solutions were made of ADIBO-TEG-biotin 3.13,238 and alkyne-TEG-biotin 3.23.129 
Examples of each stock solution used are as follows: 0.8 mg ADIBO-TEG-biotin 3.13, 
and 0.4 mg alkyne-TEG-biotin 3.23 were each weighed into separate vials and 
dissolved in 1 mL chloroform to form stock solutions of 0.71 mM 3.13, and 0.78 mM 
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3.23. In addition, a 500 µM stock solution of D-biotin was made by dissolving 1.4 mg in 
11.5 mL of 0.5X PBS buffer, pH 7.4. Using the alkyne stock solutions, 14.1 µL ADIBO-
TEG-biotin 3.13 stock and 12.8 µL alkyne-TEG-biotin 3.23 stock were measured into 
separate glass vials, dried under a stream of nitrogen, and placed under vacuum for 1 
h. To the alkyne (3.13 and 3.23) containing vials, 2 mL of 0.5X PBS, pH 7.4 buffer was 
added to provide 5 µM stock solutions of each. These stock solutions were then diluted 
into 12 solutions – 0, 0.05, 0.15, 0.3, 0.45, 0.6, 0.75, 1.0, 1.25, 1.5, 1.75, and 2.0 µM. In 
a 96-well streptavidin-coated microplate, 200 µL of wash buffer (0.5X PBS, pH 7.4) was 
added to each row to be used. The plates were then shaken for 30 min, and the wash 
buffer was then removed. For the biotin preincubation control, 100 µL of 500 µM D-biotin 
was added to each well and incubated for 1h. This solution was removed and the wells 
were washed with 3 x 200 µL wash buffer. In each case, 100 µL of the respective 
alkyne reagent (3.13 or 3.23) was added to the appropriate well. This was immediately 
followed by addition of 100 µL of 500 µM of the previously described liposome solution 
to each well. This yielded a final liposome concentration of 250 µM in each well, and 
alkyne reagent concentrations of 0, 0.025, 0.075, 0.15, 0.225, 0.3, 0.375, 0.5, 0.625, 
0.75, 0.875, and 1.0 µM in different wells. These solutions were incubated, with shaking, 
for 4 h at rt. Following incubation, the solutions were removed and each well was 
washed with 3 x 200 µL wash buffer. Water (100 µL) was then added to each well and 
fluorescence was then measured using a microplate reader with a 460 nm (± 40 nm) 




Procedure for Membrane Labeling via Fluorescent Octyne-Labeled Liposomes 
and FRET Assay  
Stock solutions of octyne-lipid 3.32 (3.05 mM), NBD-lipid (3.20 mM), and 
phosphatidylcholine (65.8 mM) were prepared in chloroform. In a glass vial, NBD-lipid 
(9.4 µL, 3%), octyne-lipid (19.7 µL, 6%), and PC (13.8 µL, 91%) were measured out and 
dried under a stream of nitrogen. The dried lipids were placed under vacuum for 1 h. 
The liposomes were hydrated using 500 µL of 20 mM HEPES, 150 mM NaCl, pH 7.4 
buffer to make a final concentration of 2 mM liposomes. The hydrated liposomes were 
rotated on a rotary evaporator for 40 min at 40 °C, freeze-thawed 10 cycles, extruded 
through 200 nm filter, and used for studies. The rhodamine-azide 3.33 used for studies 
was taken from a 0.25 mM stock solution in the same buffer. In a centrifuge tube, 45 µL 
of buffer and 25 µL of 2 mM liposomes were added and mixed. Immediately following 
addition of 50 µL of rhodamine-azide stock solution, the mixture was placed in a cuvette 
and fluorescence read. Fluorescence was measured every 60 seconds for 65 minutes 
and then plotted. 
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Chapter 4: Miscellaneous Synthetic Targets 
4.1 Optimization of a Pipemidic Acid Autotaxin Inhibitor 
In addition to DAG, PA, and the PIPns, our group is also interested in lyso-
phosphatidyl choline (LPC) and lyso-phosphatidic acid (LPA). One of the main signaling 
pathways involving these two lyso- lipids is the conversion of LPC into LPA by autotaxin 
(ATX), which works via hydrolysis of the choline headgroup.242,243 This is an important 
interaction because recent research has shown that autotaxin plays critical roles in 
normal human development and disease.244 Autotaxin has been linked to cancer 
progression, multiple sclerosis, obesity, diabetes, Alzheimer’s disease, and chronic 
pain.245 Because of autotaxin’s heavy involvement in aberrant processes, there is a 
need for specific and potent inhibitors as novel therapeutic leads. There are reported 
lipid-like inhibitors of autotaxin, but these lack many characteristics seen in 90% of 
orally bioavailable drugs. We collaborated with Drs. Parrill and Baker from the University 
of Memphis to investigate a structure–activity relationship for some novel autotaxin 
inhibitors.245 Before approaching us, they previously modeled autotaxin and found 
compound 4.1 as a novel lead inhibitor as shown in Figure 4.1.245 Working with this 
knowledge, we designed a library of compounds that could be synthesized and they 
predicted which of these compounds would be effective inhibitors. This list of predicted 
compounds greatly benefitted from the basal structure being commercially available, 
pipemidic acid, and the desired appending groups could be formed through reaction 
with a rather reactive isothiocyanate. Figure 4.3 shows the structures of all compounds 
synthesized in round one (green box), round two (red box), and round three (blue box). 
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The calculations and binding model were adjusted with each set of compounds to 
generate new lists of compounds to be synthesized and tested. In each of these cases, 
isothiocyanate compounds were reacted with pipemidic acid in the presence of 
triethylamine and subsequently purified via column chromatography to give the resulting 
thioureas that were then tested for effectiveness as an inhibitor in a FRET-based assay.  
 
Figure 4.1. Structure of the lead compound 4.1 used as the basis for generating other potential 
inihibitors and their effectiveness. 
The assays performed showed the meta-trifluoromethyl compound as having the 
strongest inhibition, while the ortho-trifluoromethyl shows the least inhibition. This study 
provides evidence that even small disturbances in chemical structures can lead to 
dramatically enhanced or decreased inhibition or binding of proteins of interest, so all 















Figure 4.2. Model of autotaxin (ATX) with the lead compound 4.1 in the binding pocket that is 





Figure 4.3. Compounds synthesized in round I (green box), round II (red box), and round III (blue 
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4.1.1 Synthetic Procedures 
General procedure for thiourea formation. To a solution of pipemidic acid in N,N-
dimethylformamide (1 mL) was added the corresponding substituted phenyl 
isothiocyanate. In some cases, triethylamine was added to speed up the reaction, while 
in others, the addition of this base led to the formation of byproducts, and was thus 
avoided. The mixture was then allowed to stir at room temperature under nitrogen 
overnight. The solvent was then removed in vacuo and the residue was extracted twice 
with methylene chloride from aqueous saturated ammonium chloride. The organic 
layers were combined, dried with magnesium sulfate, filtered and concentrated. The 
resulting crude was then purified by flash chromatography on silica gel eluting with a 
gradient of methanol in methylene chloride (0-20%) to yield the corresponding thiourea 
products (4.2–4.31). Compound purity was determined by HPLC and products were 
determined to be > 95% purity. 
 
2-(4-((4-(dimethylamino)naphthalen-1-yl)carbamothioyl)piperazin-1-yl)-8-ethyl-5-
oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.2) Pipemidic acid (25 
mg, 0.0824 mmol), 4-dimethylamino-1-napthylisothiocyanate (18.8 mg, 0.0824 mmol) 
and triethylamine (23 µL, 0.165 mmol) were used. Purification on silica yielded 4.2 (23 
mg, 53%). 1H NMR (300 MHz, CDCl3) δ 9.29 (s, 1H), 8.63 (s, 1H), 8.32-8.24 (m, 1H), 
8.02-7.93 (m, 1H), 7.62-7.46 (m, 3H), 7.02 (d, J = 7.95 Hz, 1H), 4.29 (q, J = 13.69, 6.79 





dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.3) Pipemidic acid (25 mg, 
0.0824 mmol), 4-iodophenyl isothiocyanate (21.5 mg, 0.0824 mmol) and triethylamine 
(23 µL, 0.165 mmol) were used. Purification on silica yielded 4.3 (36 mg, 77%).  1H 
NMR (300 MHz, CDCl3) δ 9.32 (s, 1H), 8.66 (s, 1H), 7.66 (d, J = 6.94 Hz, 2H) 7.37 (s, 
1H), 7.00 (d, J = 6.0 Hz, 2H) 4.33 (q, J = 8.0 Hz, 2H), 4.21-3.99 (m, 8H), 1.52 (t, J = 7.5 
Hz, 3H) ppm. 
 
2-(4-((4-carboxyphenyl)carbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.4) Pipemidic acid (25 mg, 
0.0824 mmol), 4-isothiocyanatobenzoic acid (14.8 mg, 0.0824 mmol) and triethylamine 
(23 µL, 0.165 mmol) were used. Purification on silica yielded 4.4 (23 mg, 58%). 1H NMR 
(300 MHz, DMSO) δ 9.71 (s, 1H), 9.24 (s, 1H), 8.98 (s, 1H), 7.87 (d, J = 8.53 Hz, 1H), 




dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.5) Pipemidic acid (25 mg, 
0.0824 mmol), methyl 2-isothiocyanatobenzoate (16 mg, 0.0824 mmol) and 
triethylamine (23 µL, 0.165 mmol) were used. Purification on silica yielded 4.5 (24 mg, 
59%). 1H NMR (300 MHz, CDCl3) δ 11.14 (s, 1H), 9.35 (d, J = 3.14 Hz, 1H), 8.77 (dd, J 
= 8.43, 2.41 Hz, 1H), 8.69 (d, J = 2.99 Hz, 1H), 8.01 (d, J = 6.95 Hz, 1H), 7.55 (t, J = 
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7.72 Hz, 1H), 7.12 (t, J = 7.99 Hz, 1H), 4.40-4.24 (m, 8H), 4.11 (s, 2H), 3.92 (s, 3H), 
1.52 (t, J = 7.5 Hz, 3H) ppm. 
 
8-ethyl-2-(4-((4-(morpholine-4-sulfonamido)phenyl)carbamothioyl)piperazin-1-yl)-
5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.6) Pipemidic acid 
(14.2 mg, 0.0468 mmol), 4-(morpholinosulfonyl)phenyl isothiocyanate (14 mg, 0.0468 
mmol) and triethylamine (13 µL, 0.0935 mmol) were used. Purification on silica yielded 
4.6 (24 mg, 85%). 1H NMR (300 MHz, CDCl3) δ 9.28 (s, 1H), 8.65 (s, 1H), 8.09 (s, 1H), 
7.64 (d, J = 8.71 Hz, 2H), 7.51 (d, J = 8.61 Hz, 2H), 4.43-4.01 (m, 10H), 3.80-3.70 (m, 
4H), 3.04-2.98 (m, 4H), 1.49 (t, J = 7.17 Hz, 3H) ppm. 
 
2-(4-(benzo[c][1,2,5]thiadiazol-5-ylcarbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.7) Pipemidic acid (25 mg, 
0.0824 mmol), 2,1,3-benzothiadiazol-5-yl isothiocyanate (15.8 mg, 0.0824 mmol) and 
triethylamine (23 µL, 0.165 mmol) were used. Purification on silica yielded 4.7 (24 mg, 
58%). 1H NMR (300 MHz, DMSO) δ 9.26 (s, 1H), 8.98 (s, 1H), 7.98-7.82 (m, 3H), 4.51-
4.33 (m, 2H), 4.24-3.99 (m, 8H), 1.42-1.32 (m, 3H) ppm. 
 
8-ethyl-2-(4-(mesitylcarbamothioyl)piperazin-1-yl)-5-oxo-5,8-dihydropyrido[2,3-
d]pyrimidine-6-carboxylic acid (4.8) Pipemidic acid (25 mg, 0.0824 mmol), mesityl 
isothiocyanate (14.6 mg, 0.0824 mmol) and triethylamine (23 µL, 0.165 mmol) were 
used. Purification on silica yielded 4.8 (36.6 mg, 92%).  1H NMR (300 MHz, CDCl3) δ 
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9.32 (s, 1H), 8.64 (s, 1H), 7.05 (s, 1H), 6.92 (s, 2H), 4.41-3.93 (m, 10H), 2.34-2.19 (m, 
9H), 1.50 (t, J = 6.96 Hz, 3H) ppm. 
 
2-(4-((4-(1H-pyrazol-1-yl)phenyl)carbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.9) Pipemidic acid (27 mg, 
0.0894 mmol) and 4-(1H-pyrazol-1-yl)phenyl isothiocyanate (15 mg, 0.0745 mmol) were 
used. Purification on silica yielded 4.9 (35.5 mg, 94%). 1H NMR (250 MHz, CDCl3) δ 
9.30 (s, 1H), 8.69 (s, 1H), 7.91 (s, 1H), 7.72-7.56 (m, 3H), 7.46-7.30 (m, 2H), 6.46 (s, 
1H), 4.36 (dd, J = 14.33, 6.78 Hz, 2H), 4.28-3.96 (m, 8H), 1.48 (t, J = 7.04 Hz, 3H) ppm.  
 
2-(4-(benzo[c][1,2,5]thiadiazol-4-ylcarbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.10) Pipemidic acid (25 mg, 
0.0824 mmol), 2,1,3-benzothiadiazol-4-yl isothiocyanate (16 mg, 0.0824 mmol) and 
triethylamine (23 µL, 0.165 mmol) were used. Purification on silica yielded 4.10 (10.8 
mg, 26%). 1H NMR (300 MHz, DMSO) δ 9.27 (s, 1H), 9.00 (s, 1H), 7.93 (d, J = 8.40 Hz, 
1H), 7.77-7.68 (m, 1H), 7.63 (d, J = 7.23 Hz, 1H), 4.48-4.41 (m, 2H), 4.24-3.99 (m, 8H), 
1.39 (t, J = 6.52, 3H) ppm. 
 
8-ethyl-5-oxo-2-(4-(m-tolylcarbamothioyl)piperazin-1-yl)-5,8-dihydropyrido[2,3-
d]pyrimidine-6-carboxylic acid (4.11) Pipemidic acid (54 mg, 0.177 mmol) and m-
tolylisothiocyanate (20 µL, 0.148 mmol) were used. Purification on silica yielded 4.11 
(67 mg, 100%).1H NMR (300 MHz, CDCl3) δ 9.32 (s, 1H), 8.68 (s, 1H), 7.33 (s, 1H), 
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7.24 (d, J = 9.0 Hz, 1H), 7.05-6.94 (m, 3H), 4.33 (q, J = 7.0 Hz, 2H), 4.24-3.87 (m, 8H), 
2.35 (s, 3H), 1.49 (t, J = 7.19 Hz, 3H) ppm. 
 
8-ethyl-5-oxo-2-(4-((3-(trifluoromethyl)phenyl)carbamothioyl)piperazin-1-yl)-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.12) Pipemidic acid (25 mg, 
0.0824 mmol), 3-(trifluoromethyl)phenyl isothiocyanate (12.5 µL, 0.0824 mmol) and 
triethylamine (23 µL, 0.165 mmol) were used. Purification on silica yielded 4.12 (31 mg, 
75%). 1H NMR (300 MHz, CDCl3) δ 9.32 (s, 1H), 8.74 (s, 1H), 7.63-7.60 (m, 2H), 7.51-
7.42 (m, 2H), 4.45-4.37 (m, 2H), 4.23-4.10 (m, 8H), 1.52 (t, J = 7.5 Hz, 3H) ppm. 
 
8-ethyl-5-oxo-2-(4-((2-(trifluoromethyl)phenyl)carbamothioyl)piperazin-1-yl)-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.13) ortho trifluoro (25) Pipemidic 
acid (48 mg, 0.159 mmol) and 2-(trifluoromethyl)phenyl isothiocyanate (20 µL, 0.132 
mmol) were used. Purification on silica yielded 4.13 (55 mg, 82%). 1H NMR (300 MHz, 
CDCl3) δ 9.32 (s, 1H), 8.69 (s, 1H), 7.74-7.64 (m, 1H), 7.63-7.51 (m, 2H), 7.43-7.33 (m, 
1H), 4.39-4.03 (m, 10H), 1.50 (t, J = 6.86 Hz, 3H) ppm. 
 
2-(4-((3,5-dimethylphenyl)carbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.14) Pipemidic acid (45 mg, 
0.148 mmol), 3,5-dimethylphenyl isothiocyanate (24 mg, 0.148 mmol) and triethylamine 
(41 µL, 0.296 mmol) were used. Purification on silica yielded 4.14 (41.6 mg, 67%). 1H 
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NMR (300 MHz, CDCl3) δ 9.30 (s, 1H), 8.66 (s, 1H), 7.48 (s, 1H), 6.86-6.75 (m, 3H), 
4.33 (q, J = 7.0 Hz, 2H), 4.22-3.91 (m, 8H), 2.30 (s, 6H), 1.48 (t, J = 7.11 Hz, 3H) ppm.  
 
2-(4-((3-chlorophenyl)carbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.15) Pipemidic acid (25 mg, 
0.0824 mmol), 3-chlorophenyl isothiocyanate (11 µL, 0.0824 mmol) and triethylamine 
(23 µL, 0.165 mmol) were used. Purification on silica yielded 4.15 (8.2 mg, 21%). 1H 
NMR (300 MHz, CDCl3) δ 9.03 (s, 1H), 8.51 (s, 1H), 7.10 (s, 1H), 7.04-6.93 (m, 2H), 
6.90-6.84 (m, 1H), 4.14 (q, J = 14.23, 7.04 Hz, 2H), 4.00-3.74 (m, 8H), 1.23 (t, J = 7.01 
Hz, 3H) ppm.  
 
2-(4-((2,3-dichlorophenyl)carbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.16) Pipemidic acid (51 mg, 
0.168 mmol) and 2,3-dichlorophenyl isothiocyanate (20 µL, 0.141 mmol) were used. 
Purification on silica yielded 4.16 (15.5 mg, 22%). 1H NMR (300 MHz, DMSO) δ 9.03 (s, 
1H), 8.78 (s, 1H), 7.53 (d, J = 7.43 Hz, 1H), 7.41-7.26 (m, 2H), 4.51-3.90 (m, 10H), 
1.43-1.27 (m, 3H) ppm.  
 
8-ethyl-2-(4-((3-methoxyphenyl)carbamothioyl)piperazin-1-yl)-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.17) Pipemidic acid (53 mg, 
0.175 mmol) and 3-methoxyphenyl isothiocyanate (20 µL, 0.145 mmol) were used. 
Purification on silica yielded 4.17 (36 mg, 53%). 1H NMR (300 MHz, CDCl3) δ 9.31 (s, 
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1H), 8.67 (s, 1H), 7.47 (s, 1H), 7.30-7.21 (m, 1H), 6.80-6.68 (m, 3H), 4.32 (q, J = 7.05 
Hz, 2H), 4.23-3.89 (m, 8H), 3.79 (s, 3H), 1.48 (t, J = 7.16 Hz, 3H) ppm.  
 
8-ethyl-5-oxo-2-(4-(phenylcarbamothioyl)piperazin-1-yl)-5,8-dihydropyrido[2,3-
d]pyrimidine-6-carboxylic acid (4.18) Pipemidic acid (25 mg, 0.0824 mmol), phenyl 
isothiocyanate (9.8 µL, 0.0824 mmol) and triethylamine (23 µL, 0.165 mmol) were used. 
Purification on silica yielded 4.18 (16 mg, 43%). 1H NMR (300 MHz, CDCl3) δ 9.33 (s, 
1H), 8.68 (s, 1H), 7.41-7.33 (m, 3H), 7.22-7.15 (m, 2H), 4.38-4.28 (m, 2H), 4.24-3.89 
(m, 8H), 1.49 (t, J = 7.57 Hz, 3H) ppm. 
 
2-(4-((2-chlorophenyl)carbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.19) Pipemidic acid (56 mg, 
0.184 mmol) and 2-chlorophenylisothiocyanate (20 µL, 0.153 mmol) were used. 
Purification on silica yielded 4.19 (72mg, 99%). 1H NMR (300 MHz, CDCl3) δ 9.34 (s, 
1H), 8.68 (s, 1H), 7.75 (dd, J = 8.10, 1.43 Hz, 1H), 7.44 (dd, J = 8.00, 1.48 Hz, 1H), 
7.37-7.27 (m, 2H), 7.15 (dt, J = 7.67, 1.53 Hz, 1H), 4.38-4.06 (m, 10H), 1.50 (t, J = 7.20 
Hz, 3H) ppm. 
 
2-(4-((3,5-bis(trifluoromethyl)phenyl)carbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-
5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.20) Pipemidic acid (40 mg, 
0.132 mmol) and 3,5-bis(trifluoromethyl)phenyl isothiocyanate (20 µL, 0.110 mmol) 
were used. Purification on silica yielded 4.20 (61 mg, 97%). 1H NMR (300 MHz, CDCl3) 
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δ 9.30 (s, 1H), 8.68 (s, 1H), 8.62 (s, 1H), 7.94 (s, 2H), 7.62 (s, 1H), 4.42-4.10 (m, 10H), 
1.51 (t, J = 7.07 Hz, 3H) ppm. 
 
8-ethyl-2-(4-((2-methoxyphenyl)carbamothioyl)piperazin-1-yl)-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.21) Pipemidic acid (25 mg, 
0.0824 mmol), 2-methoxyphenyl isothiocyanate (11.6 µL, 0.0824 mmol) and 
triethylamine (23 µL, 0.165 mmol) were used. Purification on silica yielded 4.21 (21.4 
mg, 55%). 1H NMR (250 MHz, CDCl3) δ 9.33 (s, 1H), 8.68 (s, 1H), 7.84 (d, J = 7.30 Hz, 
1H), 7.54 (s, 1H), 7.20-7.04 (m, 1H), 7.03-6.85 (m, 2H), 4.34 (q, J = 8.0 Hz, 2H), 4.24-
4.01 (m, 8H), 3.89 (s, 3H), 1.49 (t, J = 6.60 Hz, 3H) ppm. 
 
2-(4-((2,5-dichlorophenyl)carbamothioyl)piperazin-1-yl)-8-ethyl-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.22) Pipemidic acid (51 mg, 
0.168 mmol) and 2,5-dichlorophenyl isothiocyanate (20 µL, 0.140 mmol) were used. 
Purification on silica yielded 4.22 (42.7 mg, 60%). 1H NMR (300 MHz, CDCl3) δ 9.39 (s, 
1H), 9.06 (s, 1H), 7.57 (d, J = 2.39 Hz, 1H), 7.42-7.36 (m, 1H), 7.20 (d, J = 7.35 Hz, 
1H), 4.55-4.39 (m, 2H), 4.31-4.02 (m, 8H), 1.52 (t, J = 6.88 Hz, 3H) ppm. 
 
8-ethyl-2-(4-((4-fluorophenyl)carbamothioyl)piperazin-1-yl)-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.23) Pipemidic acid (35 mg, 
0.1154 mmol) and 4-fluorophenyl isothiocyanate (17.7 mg, 0.1154 mmol) were used. 
Purification on silica yielded 4.23 (30 mg, 57%). 1H NMR (300 MHz, CDCl3) δ 9.34 (s, 
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1H), 8.69 (s, 1H), 7.33 (s, 1H), 7.25-7.16 (m, 2H), 7.13-7.03 (m, 2H), 4.40-4.29 (m, 2H), 
4.28-3.96 (m, 8H), 1.50 (t, J = 7.36 Hz, 3H) ppm. 
 
8-ethyl-2-(4-((4-methoxyphenyl)carbamothioyl)piperazin-1-yl)-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.24) Pipemidic acid (30 mg, 
0.0989 mmol) and 4-methoxyphenyl isothiocyanate (13.7 µL, 0.0989 mmol) were used. 
Purification on silica yielded 4.24 (37 mg, 80%). 1H NMR (300 MHz, CDCl3) δ 9.33 (s, 
1H), 8.67 (s, 1H), 7.30 (s, 1H), 7.15 (d, J = 8.76 Hz, 2H), 6.90 (d, J = 8.82 Hz, 2H), 4.34 




dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.25) Pipemidic acid (58 mg, 
0.191 mmol) and 4-chlorophenyl isothiocyanate (27 mg, 0.159 mmol) were used. 
Purification on silica yielded 4.25 (50 mg, 67%). 1H NMR (300 MHz, CDCl3) δ 9.34 (s, 
1H), 8.68 (s, 1H), 7.34 (d, J = 14.13 Hz, 2H), 7.17 (d, J = 8.70 Hz, 2H), 4.39-4.28 (m, 
2H), 4.28-3.93 (m, 8H), 1.49 (t, J = 6.68 Hz, 3H) ppm. 
 
8-ethyl-5-oxo-2-(4-((4-(trifluoromethyl)phenyl)carbamothioyl)piperazin-1-yl)-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.26) Pipemidic acid (30 mg, 
0.0989 mmol) and 4-trifluorophenyl isothiocyanate (16.7 mg, 0.0824 mmol) were used. 
Purification on silica yielded 4.26 (31 mg, 77%). 1H NMR (300 MHz, CDCl3) δ 9.34 (s, 
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1H), 8.69 (s, 1H), 7.65-7.57 (m, 2H), 7.51 (s, 1H), 7.37-7.31 (m, 2H), 4.34 (q, J = 7.46, 
7.27 Hz, 2H), 4.27-3.97 (m, 8H), 1.49 (t, J = 7.25, 7.25 Hz, 3H) ppm. 
 
8-ethyl-5-oxo-2-(4-(p-tolylcarbamothioyl)piperazin-1-yl)-5,8-dihydropyrido[2,3-
d]pyrimidine-6-carboxylic acid (4.27) Pipemidic acid (89 mg, 0.293 mmol) and p-tolyl 
isothiocyanate (40 mg, 0.268 mmol) were used. Purification on silica yielded 4.27 (82 
mg, 68%). 1H NMR (300 MHz, CDCl3) δ 9.32 (s, 1H), 8.67 (s, 1H), 7.40 (s, 1H), 7.17 (d, 
J = 7.60 Hz, 2H), 7.09 (d, J = 7.44 Hz, 2H), 4.33 (q, J = 13.30, 6.75 Hz, 2H), 4.23-3.91 
(m, 8H), 2.34 (s, 3H), 1.49 (t, J = 7.03 Hz, 3H) ppm. 
 
8-ethyl-2-(4-((3-iodophenyl)carbamothioyl)piperazin-1-yl)-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.28) Pipemidic acid (40 mg, 
0.133 mmol) and 3-iodophenyl isothiocyanate (29 mg, 0.111 mmol) were used. 
Purification on silica yielded 4.28 (57 mg, 90%). 1H NMR (250 MHz, CDCl3) δ 9.33 (s, 
1H), 8.73 (s, 1H), 7.65 (s, 1H), 7.51 (s, 1H), 7.40-7.24 (m, 1H), 7.08 (s, 1H), 4.48-4.31 
(m, 2H), 4.27-3.93 (m, 8H), 1.34-1.17 (m, 3H) ppm. 
 
8-ethyl-2-(4-((2-fluorophenyl)carbamothioyl)piperazin-1-yl)-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.29) Pipemidic acid (25 mg, 
0.0824 mmol) and 2-fluorophenyl isothiocyanate (10 µL, 0.0824 mmol) were used. 
Purification on silica yielded 4.29 (24 mg, 64%). 1H NMR (300 MHz, CDCl3) δ 9.35 (s, 
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1H), 8.69 (s, 1H), 7.64 (t, J = 7.34 Hz, 1H), 7.21-7.12 (m, 3H), 4.35 (q, J = 13.56, 7.29 
Hz, 2H), 4.28-4.02 (m, 8H), 1.50 (t, J = 7.09 Hz, 3H) ppm. 
 
8-ethyl-2-(4-((3-fluorophenyl)carbamothioyl)piperazin-1-yl)-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.30) Pipemidic acid (25 mg, 
0.0824 mmol) and 3-fluorophenyl isothiocyanate (9.9 µL, 0.0824 mmol) were used. 
Purification on silica yielded 4.30 (22 mg, 59%). 1H NMR (300 MHz, CDCl3) δ 9.32 (s, 
1H), 8.66 (s, 1H), 7.41 (s, 1H), 7.37-7.27 (m, 1H), 6.96 (t, J = 7.39, 2H), 6.88 (t, J = 7.67 
Hz, 1H), 4.38-4.27 (m, 2H), 4.27-3.91 (m, 8H), 1.54-1.43 (m, 3H) ppm. 
 
8-ethyl-2-(4-((2-iodophenyl)carbamothioyl)piperazin-1-yl)-5-oxo-5,8-
dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid (4.31) Pipemidic acid (25 mg, 
0.0824 mmol) and 2-iodophenyl isothiocyanate (21.5 mg, 0.0824 mmol) were used. 
Purification on silica yielded 4.31 (35 mg, 75%). 1H NMR (300 MHz, CDCl3) δ 9.36-9.30 
(m, 1H), 8.69-8.65 (m, 1H), 7.89-7.82 (m, 1H), 7.62-7.55 (m, 1H), 7.41-7.32 (m, 1H), 









4.2 Porphyrin–Lipid Conjugates  
Photoactive complexes based on porphyrins and fullerenes have been 
extensively used in building molecular photovoltaic systems owing to efficient electron 
transfer from porphyrin to fullerene upon photoexcitation.246 Ground-state porphyrins 
absorb light very strongly at ~400 nm, but in their excited-state they have long lifetimes 
and can often exchange electrons readily with redox species in their vicinity. Because of 
the close redox potential of these excited-state porphyrins and fullerenes, a class of 
compounds known to have strong electron-accepting capability, they have often been 
used in tandem. Through collaboration with Dr. Wei Zhan at Auburn University, we have 
synthesized three lipids (shown in Figure 4.4) for use in photoconversion systems using 
electrode-supported lipid bilayers, which involves building bilayers composed of a 
porphyrin-lipid and fullerene molecules buried within the hydrophobic core of the 
bilayers. For their system, it was desirable to have the porphyrin appended to the 
headgroup of the lipid, so that it is exposed to the exterior aqueous environment. To 
achieve this, we coupled the porphyrin moiety in Figure 4.5 to the headgroup of 




Figure 4.4. Structures of three lipids synthesized. 
We received the porphyrin methyl esters, shown in Figure 4.5, from Dr. X. Peter 
Zhang at the University of South Florida. Beginning there, zinc was inserted into the 
center of the porphyrin using zinc acetate in N,N-dimethylformamide and heating at 60 
ºC overnight. The methyl ester was then deprotected with sodium hydroxide in 
methanol. Finally, the acid was coupled to the amine of PE using hydroxybenzyltriazole 
and HBTU. In addition to these porphryin lipids, Dr. Zhan was interested in the effect of 
ferrocene on these photovoltaic membrane systems. The synthesis of this ferrocene 
















































Dr. Zhan began investigating the tert-butyl porphyrin lipid, and after some testing, 
it was thought that the porphyrin portion was not hydrophilic enough to be properly 
presented outside of the membrane, so we decided a methoxy porphyrin lipid would be 
a good alternative. Upon further investigation by Dr. Zhan, it was discovered that the 
tert-butyl porphyrin lipid, in fact, was a usable and valuable compound and he obtained 
promising results.  
The studies involved in this report use electrodes as a surface for immobilizing a 
membrane bilayer. The base layer is composed of a thiol-terminated phospholipid and 
the upper layer is composed of PC and the tert-butyl porphyrin lipid conjugate. They 
discovered that the fullerene can be incorporated into the top, bottom, or both layers 
and have obtained different photocurrent responses based on the locale of the 
fullerene. The sequential formation of the bilayer allows a direct organization of these 
agents on electrodes. In this report, the best, most stable, photocurrent generation 
system was determined to be when fullerenes were incorporated in both the upper and 
lower layer. The results reported here represent the first step toward lipid-based, 































































Figure 4.6. Synthesis of ferrocene-lipid. 
4.2.1 Synthetic Procedures 
5-(4-carboxyphenyl)-10,15,20-tris-(3,5,di-tert-butylphenyl)porphyrin zinc complex 
(4.37): To the methyl ester 4.35 (25 mg, 0.025 mmol) was added 2.5 mL of N, N-
dimethylformamide and zinc(II)acetate (36.4 mg, 0.198 mmol). The solution was heated 
to 60 °C and stirred overnight. The solvent was then removed under reduced pressure 
and the residue was extracted with methylene chloride (2 x 10 mL) and water. The 
organic layers were combined, dried with magnesium sulfate, filtered, and concentrated. 
The resulting residue was dissolved in ethanol (2.5 mL) and tetrahydrofuran (2.5 mL). 























reflux overnight. The solvent was removed and the residue was extracted with 
chloroform (3 x 25 mL) and water, following neutralization with 2M hydrochloric acid to 
pH 4. The organic layers were combined, dried with magnesium sulfate, filtered, and 
concentrated. The residue was purified by chromatography on silica gel with a gradient 
of methanol–methylene chloride (0–10%) to afford the zinc-conjugated porphyrin 
carboxylic acid 4.37 (26 mg, 100%).  
1H NMR (300 MHz, CDCl3): δ = 9.07–9.05 (m, 6H), 8.95 (d, J = 4.5 Hz, 2H), 8.55 (d, J = 
7.8 Hz, 2H), 8.44 (d, J = 7.8 Hz, 2H), 8.13–8.11 (m, 6H), 7.83–7.81 (m, 3H), 1.55–1.54 
(m, 54H) ppm. 
 
5-(4-Carboxyphenyl)-10,15,20-tris-(3,5,di-methoxyphenyl)porphyrin zinc complex 
(4.38): To the methyl ester 4.36 (25 mg, 0.029 mmol) was added 2.5 mL of N, N-
dimethylformamide and zinc(II)acetate (43 mg, 0.23 mmol). The solution was heated to 
60 °C and stirred overnight. The solvent was then removed under reduced pressure and 
the residue was extracted with methylene chloride (2 x 10 mL) and water. The organic 
layers were combined, dried with magnesium sulfate, filtered, and concentrated. The 
resulting residue was dissolved in ethanol (2.5 mL) and tetrahydrofuran (2.5 mL). 
Potassium hydroxide was added (500 µL, 2M) and the resulting mixture was stirred at 
reflux overnight. The solvent was removed and the residue was extracted with 
chloroform (3 x 25 mL) and water, following neutralization with 2M hydrochloric acid to 
pH 4. The organic layers were combined, dried with magnesium sulfate, filtered, and 
concentrated. The residue was purified by chromatography on silica gel with a gradient 
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of methanol–methylene chloride (0–10%) to afford the zinc-conjugated porphyrin 
carboxylic acid 4.38 (26 mg, 100%).  
1H NMR (300 MHz, CDCl3): δ = 9.06–9.02 (m, 6H), 8.89 (d, J = 4.5 Hz, 2H), 8.49 (d, J = 
7.8 Hz, 2H), 8.34 (d, J = 7.8 Hz, 2H), 7.40–7.35 (m, 6H), 6.81 (s, 3H), 3.88 (s, 18H) 
ppm. 
 
Zinc complex 5-(4-carboxyphenyl)-10,15,20-tris-(3,5,di-t-butylphenyl)porphyrin 
phosphatidylethanolamine conjugate (4.32): To the porphyrin carboxylic acid 4.37 (9 
mg, 0.0101 mmol) was added N, N-dimethylformamide (1 mL), hydroxybenzotriazole 
(HOBt, 1mg, 0.0067 mmol), O-benzotriazole-N, N, N’, N’-tetramethyl-uronium-hexafluro-
phosphate (HBTU, 4 mg, 0.0101 mmol), and N, N-diisopropylethylamine (DIEA, 3.3 µL, 
0.0202 mmol). A solution of phosphatidylethanolamine (5 mg, 0.0067 mmol) in 
chloroform (1 mL) was added to the reaction mixture and the reaction was stirred at 
room temperature overnight. The solvent was removed and the residue was purified by 
chromatography on silica gel with a gradient of methanol–methylene chloride (0–30%). 
The resulting lipid 4.32 was obtained as a purple solid (9.5 mg, 86%). 
1H NMR (300 MHz, CDCl3:CD3OD): δ = 8.94–8.91 (m, 6H), 8.81–8.79 (m, 2H), 8.33 (d, 
J = 7.8 Hz, 2H), 8.25 (d, J = 7.8 Hz, 2H), 8.08 (s, 6H) 7.78 (s, 3H), 5.33–5.23 (m, 4H), 
4.23–4.17 (m, 3H), 4.08–4.04 (m, 2H), 3.86–3.81 (m, 3H), 3.70–3.65 (m, 5H), 2.36–2.26 





Zinc complex 5-(4-Carboxyphenyl)-10,15,20-tris-(3,5,di-methoxyphenyl)porphyrin 
phosphatidylethanolamine conjugate (4.33): To the porphyrin carboxylic acid 4.38 (9 
mg, 0.0101 mmol) was added N, N-dimethylformamide (1 mL), hydroxybenzotriazole 
(HOBt, 1mg, 0.0067 mmol), O-benzotriazole-N, N, N’, N’-tetramethyl-uronium-hexafluro-
phosphate (HBTU, 4 mg, 0.0101 mmol), and N, N-diisopropylethylamine (DIEA, 3.3 µL, 
0.0202 mmol). A solution of phosphatidylethanolamine (5 mg, 0.0067 mmol) in 
chloroform (1 mL) was added to the reaction mixture and the reaction was stirred at 
room temperature overnight. The solvent was removed and the residue was purified by 
chromatography on silica gel with a gradient of methanol–methylene chloride (0–30%). 
The resulting lipid 4.32 was obtained as a purple solid (9.5 mg, 86%).  
1H NMR (300 MHz, CDCl3:CD3OD): δ = 8.96 (s, 6H), 8.79 (d, J = 6 Hz, 2H), 8.33–8.24 
(m, 4H), 7.42–7.40 (m, 6H), 6.91–6.88 (m, 3H), 5.32–5.24 (m, 4H), 4.24–4.15 (m, 3H), 
4.10–4.03 (m, 1H), 3.97–3.95 (m, 22H), 3.86–3.80 (m, 4H), 3.68–3.65 (m, 1H), 2.36–
2.26 (m, 4H), 2.03–1.91 (m, 8H), 1.63–1.53 (m, 4H), 1.27–1.23 (m, 40H), 0.87–0.83 (m, 
6H) ppm. 31P NMR (121.5 MHz, CDCl3:CD3OD): δ = 2.02 (s, 1P) ppm.  
 
Ferrocene phosphatidylethanolamine (4.34): To ferrocene carboxylic acid 4.37 (2.4 
mg, 0.01 mmol) was added N, N-dimethylformamide (1 mL), hydroxybenzotriazole 
(HOBt, 1mg, 0.0067 mmol), O-benzotriazole-N, N, N’, N’-tetramethyl-uronium-hexafluro-
phosphate (HBTU, 3.8 mg, 0.010 mmol), and N, N-diisopropylethylamine (DIEA, 3.3 µL, 
0.0202 mmol). A solution of phosphatidylethanolamine (5 mg, 0.0067 mmol) in 
chloroform (1 mL) was added to the reaction mixture and the reaction was stirred at 
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room temperature overnight. The solvent was removed and the residue was purified by 
chromatography on silica gel with a gradient of methanol–methylene chloride (0–30%). 
The resulting lipid 4.34 was obtained as a purple solid (6.4 mg, 98%). 
1H NMR (300 MHz, CDCl3:CD3OD): δ = 5.36–5.32 (m, 4H), 5.26–5.22 (m, 2H), 4.83 (t, J 
= 1.8 Hz, 1H), 4.43–4.38 (m, 2H), 4.22 (s, 3H), 4.19–4.12 (m, 2H), 4.02–3.98 (m, 2H), 
3.68–3.66 (m, 1H), 3.60–3.56 (m, 1H), 2.31 (t, J = 7.5 Hz, 4H), 2.02 (q, J = 6 Hz, 8H), 


















4.3 Rhodamines  
Surface enhanced hyper raman spectroscopy (SEHRS) is an analytical 
technique used to detect the vibrational modes in any given molecule. This is done by 
attaching the molecule to a silver or gold surface, followed by ablation with two lasers at 
90º angles to one another, exciting the surface and the attached molecule resulting in a 
vibrational spectrum. This project has gone through various phases, with the current 
synthetic target shown in Figure 4.8. Compound 4.39 is an isomer of rhodamine 6G 
where the ethyl groups of the xanthene nitrogens have been replaced by methyls, which 
has been synthesized. This rhodamine isomer was made by refluxing 3-dimethylamino-
4-methylphenol and phthalic anhydride in 1,2-dichlorobenzene at 210 ºC overnight. This 
created the acid version of the rhodamine, which was then treated with sodium 
hydroxide and diethyl sulfate to create the ethyl ester that was then used for SEHRS. A 
deuterated version of the same molecule, with the methyls of the xanthene nitrogen fully 
deuterated, began by treating 3-hydroxy-6-methylaniline with dimethyl sulfate–d6 in 
acetonitrile overnight, and then repeating the previous rhodamine preparation 
procedure. These two molecules will be used to detect differences in SEHR spectra, 
which is a process that is still underway.  
 






















Figure 4.8. Deuterated tetramethyl rhodamine target to be used in SEHRS. 
In the previous phases of the project, there were other rhodamine targets, as 
seen in Figure 4.9. These rhodamines were designed based on calculations of the 
expected SEHRS spectra performed by the Camden group at the University of 
Tennessee at Knoxville. Theoretical calculations of the expected SEHRS spectra were 
performed as the rhodamine isomer 4.45 was being synthesized. There were some 
complications in the initial synthetic route, which included the protection of the amine 
with acetate. The removal of this acetate group proved to be problematic; therefore the 
synthetic route was adjusted to include the more easily cleaved trifluoroacetate 
protecting group. The removal of this protecting group also led to minimal success, even 
upon the addition of sodium borohydride. Before the rhodamine isomer 4.45 could be 
properly purified, an initial SEHRS experiment was undertaken with the impure product 
and the spectra did not show much difference from rhodamine 6G. Based on theoretical 
calculations, it was determined that another pair of rhodamine isomers, 4.39 and 4.41, 





































Figure 4.9. Previous synthetic rhodamine target. 
 
4.3.1 Synthetic Procedures 
Tetramethylrhodamine (4.39): To 3-(dimethylamino)-4-methylphenol (146 mg, 0.97 
mmol) was added phthalic anhydride (72 mg, 0.48 mmol) and 1,2-dichlorobenzene (30 
mL). A Dean-Stark trap was placed on the flask, tightly wrapped with glass wool and 
foil, and stirred at 220 °C overnight. The next day, the reaction was cooled to room 
temperature, and sodium hydroxide (19 mg, 0.48 mmol) and diethylsulfate (88 µL, 0.67 
mmol) were added. The reaction was heated to 110 °C and stirred overnight. The 
solvent was then removed under reduced pressure and the residue was purified by 
column chromatography on silica gel with a gradient of ethyl acetate/hexanes (25–
100%). The collected product was then dried and then dissolved in ethanol (5 mL). 
Potassium bromide (10 mL, 14% solution) was added and the reaction mixture was 
stirred at rt overnight. The reaction mixture was concentrated and the rhodamine 









































1H NMR (300 MHz, CDCl3): δ = 8.30 (d, J = 9.0 Hz, 1H), 7.83–7.71 (m, 2H), 7.33 (d, J = 
9.0 Hz, 1H), 7.09 (d, J = 9.0 Hz, 2H), 6.94–6.88 (m, 4H), 4.03 (q, J = 7.0 Hz, 2H), 3.34 
(s, 12H), 1.01 (t, J = 7.5 Hz, 3H) ppm. MALDI-HRMS: calcd. for C28H31N2O3 [M + H]+ 
443.2335; found 443.2459. 
 
3-(Dimethyl-(d6)-amino)-4-methylphenol (4.40): To 3-amino-4-methylphenol (200 mg, 
1.62 mmol) dissolved in acetonitrile (10 mL) was added dimethyl sulfate-d6 (154 µL, 
1.624 mmol) and the reaction was stirred at rt overnight. The solvent was then removed 
and the residue purified by chromatography on silica gel with a gradient of ethyl 
acetate–hexanes (50–100%) to methanol–dichloromethane (3%) to afford 4.40 (98 mg, 
38%).  
1H NMR (500 MHz, CDCl3): δ = 6.87–6.85 (m, 1H), 6.14 (s, 2H), 2.04 (s, 3H) ppm. 2H 
NMR (500 MHz, CDCl3:CD3OD): δ = 2.79 (s, 6D) ppm. 13C NMR (500 MHz, CDCl3): δ = 
155.74, 148.34, 130.43, 114.01, 103.37, 97.58, 77.37, 16.51 ppm. DART-HRMS: calcd. 
for C9H7D6NO [M + H]+ 158.1448; found 158.1452. 
 
N-Ethyl-2,2,2-trifluoro-N-(5-hydroxy-2-methylphenyl)acetamide (4.42): To a round 
bottom flask was added 3-(ethylamino)-4-methylphenol (500 mg, 3.31 mmol) and 
cooled in an ice bath for 10 mins. Trifluoroacetic anhydride (1.18 mL, 8.47 mmol) was 
slowly added with stirring. After 3 h, the reaction mixture was concentrated and the 
resulting residue was purified by chromatography on silica gel with a gradient of ethyl 
acetate–hexanes (20–60%) to obtain the product 4.42 (496 mg, 61%).  
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1H NMR (300 MHz, CDCl3): δ = 7.13 (t, J = 4.5 Hz, 1H), 6.88 (d, J = 8.3, 2.6 Hz, 1H), 
6.69–6.66 (m, 1H), 4.25–4.13 (m, 1H), 3.23–3.19 (m, 1H), 2.12 (s, 3H), 1.18 (t, J = 7.2 
Hz, 3H) ppm. 19F NMR (272 MHz, CDCl3): δ = -68.92 ppm. 
 
N-Ethyl-2,2,2-trifluoro-N-(4,6-dideutero-5-hydroxy-2-methylphenyl)acetamide 
(4.43): To protected phenol 4.42 (2.13 g, 8.62 mmol) was added methylene chloride (5 
mL) and sulfuric acid-d2 (5 mL) and stirred at rt overnight. The resulting product was 
poured onto a solution of saturated sodium carbonate (100 mL) and brought to pH 7 
with conc. sulfuric acid. The mixture was then extracted with methylene chloride (2 x 40 
mL). The organic layers were combined, dried over magnesium sulfate, filtered, and 
concentrated. The resulting deuterated product 4.43 (1.08 g, 50%) was used without 
further purification. 1H NMR (300 MHz, CDCl3): δ = 7.12 (d, J = 8.5 Hz, 1H), 6.86 (dd, J 
= 8.4 Hz, 0.25H, residual H not exchanged for D), 6.69 (s, 0.25H, residual H not 
exchanged for D), 4.27–4.16 (m, 1H), 3.24–3.12 (m, 1H), 2.14 (s, 3H), 1.19 (t, J = 7.2 
Hz, 3H) ppm. 19F NMR (272 MHz, CDCl3): δ = -68.91 ppm. 13C NMR (75 MHz, CDCl3): δ 
= 157.86, 157.38, 156.91, 156.44, 154.43, 137.52, 131.87, 126.93, 121.96, 118.14, 
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